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ABSTRACT 
 
 
EVALUATION OF PILO SUBSTRATE SPECIFICITY USING  
 
NORMALLY NON-GLYCOSYLATED PROTEINS  
 
IN PSEUDOMONAS AERUGINOSA 
 
 
 
 
 
By 
 
Matthew A. Henkel 
 
May 2009 
 
 
 
Thesis Supervised by Dr. Peter A. Castric 
 
P. aeruginosa 1244 (PA1244) possesses an O-linked glycosylation system by 
which the glycosyltransferase, PilO, transfers a single preassembled O-antigen repeating 
unit to the C-terminal serine residue of pilin as a posttranslational modification.  Previous 
work has shown that the group II pilin of PA103 can be engineered for glycosylation by 
extending a C-terminal serine away from the surface with a short stretch of alanine 
residues (Horzempa et al., 2006a).  As an extension of that study, several normally non-
glycosylated proteins [PA683 pilin, PA1244 PilA-E. coli (EC) alkaline phosphatase 
(PhoA) fusion, and EC PhoA] were engineered with C-terminal amino acid extensions 
and assessed for glycosylation by PilO-mediated glycan modification.  Migration patterns 
on SDS-PAGE and an electrofocusing gel revealed that the TfpY accessory protein does 
not directly confer a posttranslational modification to group III PA683 pilin.  The 
addition of two C-terminal peptide extensions, an –AAS tripeptide and a 15 amino acid  
v 
PA1244 derived-peptide tail, to PA683 pilin allowed glycosylation in an LPS 
polymerization mutant, PA103 wzyPaO11::aacC1, when complemented with PilO.  A  
PA1244 PilA-EC PhoA fusion and EC PhoA engineered with the C-terminal –AAS 
tripeptide extension were unable to be glycosylated in strain 1244 or PA103 
wzyPaO11::aacC1 complemented with PilO.  These results suggest the necessity of pilin-
specific structures, or the necessity of a membrane anchor for enhancement of PilO 
substrate recognition.  Additionally, larger peptide tail extensions should be considered 
for testing in future work.  Overall, these findings provide further information on 
glycosylation substrate specificity and suggest the ability to glycosylate normally non-
glycosylated proteins in an effort to produce potential conjugate vaccine components.   
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I.  INTRODUCTION 
 
 
 
A.  Pseudomonas aeruginosa 
Pseudomonas aeruginosa is a gram-negative, rod-shaped eubacterium commonly 
characterized by its ubiquitous inhabitance and opportunistic pathogenicity.  P. 
aeruginosa is a member of the class Gamma Proteobacteria and the family 
Pseudomonadaceae.  Motility is conferred by the presence of flagella and pili, which 
promotes diverse habitation and success as a pathogen.  Colonized growth emits a 
discernible “grape-like” odor.   
The earliest suspected reports of P. aeruginosa infection occurred around 1860, 
but this bacterium was not identified as P. aeruginosa until about 35 years later (Colwell, 
1965; Anzai et al., 2000; Lyczak et al., 2000; El-Banna, 2007).  P. aeruginosa was first 
isolated in 1982 by Gessard and named Bacillus pyocyaneus because of the characteristic 
blue-colored purulence at infection sites (Figure 1) (Lyczak et al., 2000).  Pyocyaneus 
can be etymologically broken down to mean “blue pus.”  The root word is “cyan,” which 
means blue, and the prefix, “pyo-,” which means pus.  The secreted compound 
responsible for this blue pus was identified and aptly named pyocyanin by Fordos, as 
cited by Gamgee and Gaby (Gamgee, 1880; Gaby, 1945).  Pyocyanin is a blue colored, 
redox-active phenazine pigment that serves as a P. aeruginosa virulence factor by 
activating reactive oxygen species (ROS) (O'Malley et al., 2003; Lau et al., 2004).  
Various sources have cited the cytotoxicity of this compound (O'Malley et al., 2003; Lau 
et al., 2004; Allen et al., 2005; Reszka et al., 2006).  As another unique physiological 
characteristic, P. aeruginosa has the ability to respire under anaerobic conditions using 
2 
nitrate as the terminal electron acceptor (Schreiber et al., 2007).  Recently, nitrate 
respiration has been shown to play a role in the potentiation of pathogenicity in the cystic 
fibrosis lung, which harbors readily accessible and sufficient levels of nitrate for 
respiration (Palmer et al., 2007; Van Alst et al., 2007).   
 
Figure 1.  Several skin ulcerations infected with Pseudomonas aeruginosa.  The blue-
green color is a physical characteristic of P. aeruginosa infections caused by the 
production of pyocyanin (White & Cox, 2006).   
 
The Pseudomonas aeruginosa genome is 6.3 million base pairs and contains 
5,570 predicted open reading frames (Stover et al., 2000; LaBaer et al., 2004).  As one of 
the largest bacterial genomes, the potential proteome is anticipated to near the complexity 
of simple eukaryotes such as Saccharomyces cerevisiae (Stover et al., 2000; LaBaer et 
al., 2004).  It is speculated that the proteomic depth of this large bacterial genome is what 
allows P. aeruginosa to survive in a variety of environments (Stover et al., 2000).  This 
facultative anaerobe has been shown to inhabit various soil environments, fresh water, 
marine water, other organisms (i.e. plants, nematodes, moths, mice), people, and human-
made products (Glessner et al., 1999; Matar et al., 2005; Wade et al., 2005).   
As an infectious microbe, the P. aeruginosa genome possesses a plethora of genes 
devoted to virulence.  These virulent effectors will be discussed in more detail below.  
Specifically, P. aeruginosa has demonstrated infectivity in plants, insects, and animals 
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(Mahajan-Miklos et al., 1999; Jander et al., 2000; Rahme et al., 2000; Gallagher & 
Manoil, 2001; Choi et al., 2002).  Although P. aeruginosa can be found in the gut of 
healthy individuals (6-12 %), it should be noted that this bacterium is not native flora and 
fauna of the human digestive tract (Shooter, 1971; Griffith et al., 1989; Ohara & Itoh, 
2003; Vedantam & Hecht, 2003; Sears, 2005; Rekha et al., 2006).  Most significantly, P. 
aeruginosa is an opportunistic pathogen, only infecting those susceptible through 
compromised immune defenses.  Due to natural resistance of P. aeruginosa to common 
antimicrobials and disinfectants, this pathogenic microbe readily gains access to 
susceptible individuals at medical treatment facilities (Lyczak et al., 2000; Romao et al., 
2005).  In particular, P. aeruginosa has been isolated from hospital staff members, 
patients, wash areas, water, and virtually all medical equipment (Beatty et al., 2005; 
Matar et al., 2005).   
 
 
B.  Pseudomonas aeruginosa and Pathology  
It is the combination of tolerance for a diverse array of habitats and the presence 
of multiple virulence factors that make P. aeruginosa an opportunistic pathogen.  P. 
aeruginosa is considered an opportunistic pathogen because it is able to cause disease in 
individuals that are unable to launch a protective immune response against normally non-
pathogenic foreign microbes, but is generally a non-threat to healthy individuals.  
Individuals most readily afflicted by P. aeruginosa infections are those who suffer from 
cystic fibrosis, chronic obstructive pulmonary disorder (COPD), cancers, immune 
deficiency disorders, and severe burns. These patient populations tend to have 
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insufficient immune responses against P.aeruginosa, propagating the severity of 
infection.   
Infections by Pseudomonas generally lead to familiar pathological symptoms and 
conditions characteristic of other bacterial infections.  Some general symptoms of P. 
aeruginosa infection include fever, headache, blue colored purulence, chills, nausea, 
diarrhea in new borns, and slight pain (Bobo et al., 1973; Ratnam et al., 1986; Baruchin 
et al., 1996; Lyczak et al., 2000). Infectivity may arise in vulnerable individuals from 
intravenous drug use, hospital stays after invasive surgery, or from machines that assist in 
breathing.   
As mentioned earlier, P. aeruginosa has been shown to inhabit a wide range of 
habitats, from the clothing and skin of our fellow homo sapiens to almost all medical 
equipment.  Due to its high prevalence in hospitals, P. aeruginosa is a leading cause of 
gram-negative nosocomial infections (Weinstein, 1998).  Nosocomial infections are those 
acquired from hospitals.  P. aeruginosa is the second leading cause of nosocomial 
pneumonia infections, accounting for 20% of these infections in hospitals nationwide 
(Beatty et al., 2005; Matar et al., 2005).  P. aeruginosa does not only cause nosocomial 
pneumonia infections, it is capable of infecting all types of tissue, and accounts for about 
10-29% of all nosocomial tissue infections in the United States (Vincent, 2003; Beatty et 
al., 2005; Matar et al., 2005). The first leading cause of nosocomial infections can be 
attributed to infection by the gram-positive Staphylococcus aureus (Vincent, 2003). 
Tissues commonly susceptible to infection by Pseudomonas aeruginosa are the 
heart, blood, bones, joints, central nervous system, eyes, ears, urinary tract, lungs, 
gastrointestinal tract, and skin (Foca, 2002).  P. aeruginosa infection affecting the heart 
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can lead to endocarditis, which usually affects the valves of the heart and can evolve into 
more serious heart conditions (Venkatesan et al., 2005).  P. aeruginosa infection of the 
blood can lead to a condition of bacteria in the blood called bacteremia, which can further 
progress to septic shock.  Bacteremia is especially dangerous to those who acquire a P. 
aeruginosa infection because the blood may spread the infection to other tissues 
(Mencacci et al., 2006; Lodise et al., 2007).  P. aeruginosa infections have been found in 
bones and joints, as well as in prosthetic replacements (Calza et al., 2002; Sauer et al., 
2005).  Infection in the central nervous system may lead to the development of meningitis 
as a result of an inflammatory response (Schina et al., 2006; Huang et al., 2007).  P. 
aeruginosa infection of the ear can cause swimmer’s ear (Wang et al., 2005).  
Immunocompromised patients that rely on respirators or portable oxygen supplies, such 
as those with COPD, are extremely susceptible to lung infection leading to pneumonia.  
A Brazilian study of a university hospital showed that P. aeruginosa ventilator-acquired 
pneumonia occurred in 22% of patients on respiratory devices (Guimaraes & Rocco, 
2006).  As with respirators, hospital patients can also acquire a Pseudomonas urinary 
tract infection from catheters (Jones et al., 2006; Shigemura et al., 2006).  P. aeruginosa 
infections can potentiate in the digestive tract by route of percutaneous endoscopic 
gastrostomy tubes, nasogastric tubes, or nosocomial infections after surgery, such as an 
appendectomy or implantation of an occluded bile duct stent (Kasatpibal et al., 2005; 
Segal et al., 2006; Demirbag et al., 2007).  P. aeruginosa can also cause a skin rash in 
immunocompetent individuals often referred to as “hot tub folliculitis,” from the most 
common site of exposure (Yu et al., 2007).   
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Pseudomonas infection can be detected by laboratory cultures taken from the site 
of infection.  These infections are extremely difficult to treat due to P. aeruginosa’s 
general resistance to antibiotics.  As a result, extreme standards of sanitation in 
conjunction with a combination of antibiotics are usually administered to treat 
Pseudomonas infections (Baltch & Smith, 1985). 
 
1.  Cystic Fibrosis  
Although a very serious threat to all immunocompromised individuals, P. 
aeruginosa pathogensis has been characterized most thoroughly in cystic fibrosis 
respiratory infections, severe burn infections, and ocular keratitis.  P. aeruginosa 
infections account for greater than 90% of deaths in cystic fibrosis patients (Corech et al., 
2005).  Cystic fibrosis is a genetic disorder that displays aberrant mucosal secretion in the 
respiratory tract, pancreas, small intestine, and male reproductive tract (Wine, 1995; 
Sheppard & Ostedgaard, 1996; Rosenstein & Zeitlin, 1998).  Cystic fibrosis results from 
a mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene 
located on chromosome 7 (Riordan et al., 1989; Stanke et al., 2008).  This gene encodes 
an apical epithelial membrane-embedded chloride channel that is responsible for the 
transport of chloride, bicarbonate, and glutathione upon cAMP activation (Stanke et al., 
2008).  Cystic fibrosis patients are immunocompromised because their respiratory tract is 
unable to provide essential immune responses.  Because cystic fibrosis patients must 
receive more frequent medical attention, they are predisposed to an increased risk of 
developing a nosocomial pneumonia or respiratory tract infection.   
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Studies have shown that CFTR mutations affect a cystic fibrosis patient’s ability 
to clear P. aeruginosa infections.  For example, an aberrant CFTR mutation, alone, 
increases inflammatory responses and provides a suitable environment for the 
establishment of a P. aeruginosa infection (Pier et al., 1996; Lyczak et al., 2000; van 
Heeckeren et al., 2005).  The CFTR protein may serve as an epithelial cell immune-
receptor for P. aeruginosa clearance (Schroeder et al., 2002).  Specifically, Pier et al. 
identified the core oligosaccharide of Pseudomonas aeruginosa as the ligand for the 
CFTR protein (Zaidi et al., 1996; Schroeder et al., 2002).  When this gene is mutated, as 
in cystic fibrosis, P. aeruginosa is not internalized by the epithelial cells, and may more 
easily establish colonization (Pier et al., 1996; Pier et al., 1997; Schroeder et al., 2001; 
Cannon et al., 2003).  Once colonization is facilitated, P. aeruginosa secretes an 
exopolysaccharide called alginate, which results in the transition from a non-mucoid to a 
mucoid growth phenotype (DeVries & Ohman, 1994).  This mucoid phenotype, along 
with the mutant CFTR aberrant exocrine phenotype, interferes with ciliary clearance and 
the delivery of host defenses (Read et al., 1992; Cowely et al., 1997; Noone et al., 2004).  
The inability to physically clear the respiratory tract harbors trapped immune cells which 
eventually lyse and become part of the mucoid matrix (Kirchner et al., 1996).  Additional 
factors, such as flagellum, pili, and O-antigen have been shown influential in the 
establishment of P. aeruginosa infections in cystic fibrosis patients, while multiple 
excreted proteases have been shown influential in the maintenance of infection in this 
patient population (Lyczak et al., 2000).   
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2.  Severe Burns  
 As with cystic fibrosis, severe burn patients often fall victim to the omnipresent 
existence and multiple virulence factors of P. aeruginosa.  For severe burn victims, loss 
of skin tissue means the loss of a principal anatomic barrier of the innate immune system.  
Although flagella and pili play an important role in facilitation and spread of infection, 
secreted enzymes such as, exotoxin A, elastases, phospholipase C, type III secretion 
proteins, and alkaline protease all have been shown to be important in the maintenance of 
infection by compromising host defenses.  In general these proteases have been shown to 
break down collagen in healing skin epithelium, degrade immunoglobulins, degrade 
complement proteins, and indirectly affect the ability of the host to recruit immune cells 
to burn sites (Lyczak et al., 2000).  It has been shown that an inherent characteristic of 
thermal injury is the decrease of polymorphonuclear cell Fc receptors (Jeyapaul et al., 
1984).  Fc receptors bind immunoglobulins to target a foreign antigen for clearance.  Not 
only is P. aeruginosa destroying immunoglobulins at the site of infection, but with the 
decrease in Fc receptors, immunoglobulin-mediated defenses are greatly diminished.  
One study showed that administration of host-derived polyclonal antibodies to infection 
sites restored ability to fight infection in a murine burn model (Felts et al., 1999).  It is 
the inability to deliver host immune defenses to the site of infection that ultimately 
manifests the scenario of systemic spread and subsequent death in severe burn victims 
(Ha & Jin, 1999).    
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3.  Contact Lens Wear 
 P. aeruginosa infection of the eye threatens eyesight of even healthy individuals.  
P. aeruginosa infection of the cornea is also referred to as ulcerative keratitis.  The 
cornea is the outer, clear layer of epithelial cells that serves as a barrier between the 
inner-eye anatomy (pupil, iris, lens, etc.)  and the external environment.  Because the 
cornea is the outer-most tissue layer of the eye, it must rely on specific innate immune 
responses, such as tear production and the blink reflex, in addition to standard immune 
responses, to combat the readily encountered pathogens from the external environment.  
The most commonly affected are those that wear contacts.  Multiple studies have shown 
that about 40% of all contact lens-related cases of keratitis are a result of P. aeruginosa 
(Ormerod & Smith, 1986, Yu et al., 2007; Watt & Swrbrick, 2007).  Studies have also 
shown that contact lenses can decrease secreted IgA, mucins, and overall effective tear 
production, leading to increased susceptibility to bacterial infection (Versura et al., 1987; 
Cheng et al., 1996; Pearce et al., 1999; Hori et al., 2006; Berry et al., 2008).  Upon P. 
aeruginosa inoculation of the eye, virulence factors such as flagella, pili, alkaline 
protease, exotoxin A, and protease IV have all been shown to establish and maintain 
infection (Gupta et al., 1994; Gupta et al., 1996; Engel et al., 1998; Fleiszig et al., 2001; 
Pillar & Hobden, 2002; Zhang et al., 2003).  P. aeruginosa LPS has been shown to play a 
special role in maintenance of infection.  As mentioned earlier, the CFTR protein is 
suspected to act as an immune-receptor of epithelial cells to internalize and diminish 
establishment of infection.  In the cornea epithelial cells, CFTR is also expressed and 
shown to interact with P. aeruginosa LPS core.  However, unlike apical epithelial cells of 
the respiratory tract that can safely be removed from the infection site after P. aeruginosa 
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internalization, corneal epithelial internalization does not yield the same host success.  
The corneal epithelium recruits phagocytes and other polymorphonuclear cells to the site 
of infection, where these immune cells, in an attempt to clear the infection through 
phagocytosis and release of various proteases and reactive oxygen species, cause 
devastating damage to the surrounding corneal tissue, compromising vision (Zaidi et al., 
1996; Lyczak et al., 2000).  For contact lens users, this corneal cell binding and 
internalization can occur as quickly as 24 hours after lens wear (Ladage et al., 2004).   
 It is the presence of numerous virulence factors that allow P. aeruginosa to 
exploit and evade weakened immune defenses.  The next section will provide a brief 
overview of some of the most well characterized virulence factors of P. aeruginosa.  
 
 
C.  Virulence Factors  
Although P. aeruginosa has access to human hosts through a multitude of 
environmental media, P. aeruginosa could not survive as an opportunistic pathogen 
without the presence of virulence factors to colonize, damage, and evade host defense 
responses.   
 
1.  Antibiotic Resistance  
The most clinically-intimidating virulent characteristic that P. aeruginosa 
possesses is antibiotic resistance.  Specifically, P. aeruginosa has been shown to be 
resistant to classes of antibiotics such as β-lactams, chloramphenicol, glycopeptides, 
quinolones, and tetracyclines (Li et al., 1995; Aeschlimann, 2003; Hocquet et al., 2007).   
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P. aeruginosa has evolved anti-microbial drug resistance through adaptations of the cell 
membrane and mutations in gene production and function.  The outer membrane, along 
with accompanying LPS layer, produces a barrier of low permeability to many 
extracellular molecules (Rocchetta et al., 1999; Lambert, 2002).  Alginate, a secreted 
polysaccharide that promotes bacterial colonization, has been shown to bind cationic 
molecules, conferring antibiotic resistance to cationic aminoglycosides (Lambert, 2002).   
Additionally, various membrane-embedded porins play a part in transferring 
hydrophilic molecules across the lipid bilayers.  In particular, loss of the oprD gene, 
which encodes a porin protein used for the acquisition of positively charged amino acids, 
has been shown to block the uptake of cationic glycopeptide anti-microbials (Lambert, 
2002).  OprF is the major outer membrane porin of P. aeruginosa.  Although it possesses 
a larger channel size than other enteric porins, OprF has been shown to be structurally 
and functionally similar to the major E. coli outer membrane protein, OmpA (Hancock, 
1984; Hancock & Brinkman, 2002).  Despite the channel size of OprF and elevated 
prevalence in the outer membrane, it has been shown that less than 1% of these proteins 
are functional.  This decrease in porin activity is believed to be an additional factor that 
influences the low permeability of P. aeruginosa’s outer membrane (Benz & Hancock, 
1981; Nicas & Hancock, 1983; Hancock, 1984; Nestorovich et al., 2006).  P. aeruginosa 
produces β-lactamase enzymes that degrade β-lactam antibiotics (Rocchetta et al., 1999; 
Lambert, 2002).  P. aeruginosa also possesses four membrane-embedded drug-efflux 
pump complexes, MexA-MexB-OprM, MexC-MexD-OprJ, MexE-MexF-OprN, and 
MexX-MexY-OprM, which have been shown to be randomly overexpressed in up to 75% 
of mutant clinical isolate strains (Aeschlimann, 2003).  The latest findings suggest 
12 
genetic mutations that increase the resistance of P. aeruginosa to anti-microbials, such as 
over-production of drug-efflux pumps, do not appear to compromise overall fitness of the 
organism (Hocquet et al., 2007).   
 
2.  Cell Behavior  
Quorum Sensing   
Quorum sensing allows neighboring cells to communicate through the secretion 
of species-specific signals and other chemotactic extracellular signals.  A bacterial cell, 
such as Pseudomonas, can produce and excrete a homoserine lactone-based autoinducer.  
As cell density increases, the intracellular levels of this autoinducer build up.  At a 
specific threshold concentration, the autoinducer activates a transcriptional activator 
protein, which activates thousands of synchronized genes in the cells of a growing 
bacterial colony.  In P. aeruginosa, two cell-to-cell signaling pathways work together to 
produce virulence factors and expand colonization.  These two cell-to-cell signaling 
pathways are (1) the las pathway and (2) the rhl pathway.  These quorum sensing systems 
lead to the spread of colonization, biofilm formation, and overall synchronization of 
global gene regulation (Van Delden & Iglewski, 1998; Whiteley et al., 1999; Schuster et 
al., 2003).   
 
Biofilm Formation 
When P. aeruginosa forms a biofilm, the cells are in an altered growth state 
where they are imbedded in an exopolysaccharide-based matrix, mainly composed of 
alginate, DNA, and immune cell debris, with synchronized gene expression, loss of LPS 
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O-antigen, and no motility (Rocchetta et al., 1999; Parsek & Singh, 2003; Allesem-Holm 
et al., 2006; Bjarnsholt & Givskov, 2007).  A defining characteristic of biofilms, as a 
virulence factor, is the expression of membrane protein lectin B (LecB) (Tielker et al., 
2005).  P. aeruginosa uses LecB to bind to host cells, such as lung epithelial cells.  One 
extracellular signaling molecule that is directly involved in biofilm formation, N-3-
oxododecanoyl homoserine lactone (OdDHL), has been shown to posses the ability to 
disrupt T-cell proliferation, leading to the inhibition of T-cell differentiation and cytokine 
secretion (Tateda et al., 2003; Ritchie et al., 2005).   
The formation of a biofilm offers P. aeruginosa resistance to antibiotics and host 
defenses (Allesen-Holm et al., 2006; Garcia-Medina et al., 2005; Sarkisova et al., 2005).  
In general, it has been shown that early contact with the respiratory epithelium allows P. 
aeruginosa to form biofilm-like colonization, which may contribute to prolonged or 
chronic infections through the physical retardation of host clearing mechanisms as well as 
the many secreted signals that interact with the respiratory epithelium on a molecular and 
cellular level (Garcia-Medina et al., 2005; Yeh et al., 2005). 
 
3.  Secreted Proteins 
Exotoxin A 
Exotoxin A (ETA) is a secreted cytotoxin that enters host cytoplasm via receptor-
mediated endocytosis and targets protein synthesis (Alcorn et al., 2004; Yates et al., 
2005).  Specifically, ETA blocks protein synthesis at the translational level by ADP 
ribosylating translational elongation factors.  However, recent studies have shown that 
the ability of ETA to halt protein synthesis in a host cell is not the defining function of 
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ETA targeted cell destruction (Jenkins et al., 2004).  Specifically, Jenkins et al. showed 
that exotoxin A functions in human mast cell death by inducing apoptosis via caspase 
cascade pathways and decreasing expression of anti-apoptotic proteins (Jenkins et al., 
2004).   
 
Elastase 
P. aeruginosa also secretes a number of proteases such as elastase, protease IV, 
and alkaline protease that cleave proteins necessary for host survival (Alcorn et al., 
2004).  Two prominent elastase proteins are LasA and LasB.  These proteins are 
regulated by the Las and Rhl quorum-sensing pathways, interact with the type III 
secretion system by regulating exo-enzyme expression, and play a role in host epithelial 
cell invasion (Cowell et al., 2003).  Alcorn et al. have shown that elastase from P. 
aeruginosa has the ability to degrade pulmonary surfactant D, impairing immune 
responses, in cystic fibrosis patients (Alcorn et al., 2004).  Since cystic fibrosis patients 
express low levels of this protein as is, elastase serves as a key virulence feature of P. 
aeruginosa in these patients (Beatty et al., 2005).   
 
Protease IV 
Protease IV cleaves at C-terminal regions of lysine-containing target proteins 
(Engel et al., 1998).  In particular protease IV has been shown capable of cleaving some 
immunologically significant proteins such as complement components, 
immunoglobulins, plasmin, plasminogen, fibrinogen, surfactant protein A, surfactant 
protein B, and surfactant protein D (Engel et al., 1998; Caballero et al., 2001; Malloy et 
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al., 2005).  Not only does protease IV enhance P. aeruginosa virulence during lung 
infection with the degradation of surfactant proteins, it has also been shown to enhance 
virulence in P. aeruginosa keratitis by degradation of corneal and intrastromal ocular 
tissues (O’Callaghan et al., 1996; Malloy et al., 2005).  Additionally, in corneal infection, 
protease IV has shown to be immunoevasive (Thibodeaux et al., 2005).   
 
Alkaline Protease 
Alkaline protease is an exo-protease that exerts its most virulent effects in P. 
aeruginosa keratitis, and often in conjunction with protease IV and elastase (Howe & 
Igluewski, 1984; O’Callaghan et al., 1996; Bandara et al., 2006).  In a mouse corneal 
infection model, alkaline protease secretion was shown to be necessary for initiation and 
maintenance of infection (Howe & Igluewski, 1984).  Alkaline protease, along with 
elastase, has been shown to play a role in the invasive infiltration into ocular tissues 
(Bandara et al., 2006).  To a greater extent than elastase, an alkaline protease possessing 
additional N-terminal leucine-lysine residues has been shown to target key 
proinflammatory cytokines, IL-6 and IL-8, thereby providing P. aeruginosa with another 
immunoevasive virulence mechanism (Matheson et al., 2006).  
 
Phospholipase C 
Phospholipase C (PLC) is an excreted P. aeruginosa virulence enzyme that 
generally targets the cleavage of phosphate groups from phospholipid molecules.  P. 
aeruginosa secretes PLC in several pathogenically favorable forms, hemolytic 
phospholipase C (PlcH), non-hemolytic phospholipase C (PlcN), and the bioinformatics-
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discovered phospholipase C (PlcB) (Dubouix et al., 2004; Barker et al., 2004; Okino & 
Ito, 2007).  PlcH targets phosphatidylcholine (PC), lyso-PC, and sphingomyelin (Okino 
& Ito 2007).  PlcN targets PC and phosphatidylserine (PS) (Okino & Ito, 2007).  PlcB 
targets PC and phosphotidylethanolamine (PE) (Barker et al., 2004; Okino & Ito, 2007).  
Hemolytic phospholipase C has the potential to exert its degradative effects on a variety 
of host tissues (Lisa et al., 1994; Wieland et al., 2002).  Specifically, PlcH has been 
shown to increase vascular and systemic damage in P. aeruginosa infected mice 
(Wieland et al., 2002).  In vivo mouse studies have shown PlcH to be responsible for 
vascular epithelial necrosis, peritoneal epithelial necrosis, and to target the liver, kidneys, 
and spleen (Berk et al., 1987; Meyers et al., 1992).  In vitro studies suggest that PlcH is 
cytotoxic to human leukocytes (Meyers et al.,1992).  Non-hemolytic phospholipase C has 
not been shown to have any virulent effects on host tissue (Wieland et al., 2002).  PlcB is 
used by P. aeruginosa as a chemotactic sensor for twitching motility towards PC and PE 
(Barker et al., 2004).   
 
Type III Secretion 
The basic structures of the type III secretion system consists of a basal, flagellum-
like membrane-embedded complex of proteins and a secretory pilus-like needle made of 
a single polymerized protein monomer, which is collectively referred to as an injectisome 
complex (Cornelis, 2006; Quinaud et al., 2007).  The type III secretion system allows P. 
aeruginosa to inject cytotoxic proteins, exotoxin S, exotoxin T, exotoxin U, and exotoxin 
Y, directly into host cytoplasm.  Collectively, these toxins inactivate immune cells, 
damage host tissue, and overall, impair immune responses (Galan & Collmer, 1999; 
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Epelman et al., 2004; Ader et al., 2005; Corech et al., 2005; Rietsch et al., 2005; Vance 
et al., 2005; Cowell et al., 2005; Cuzick et al., 2006; Shafikhani et al., 2008; Soong et al., 
2008).  ExoS is a multi-functional enzyme that possesses a N-terminal Rho GTPase 
activating (RhoGAP) domain, and an ADP ribosyl transferase (ADPRT) domain, and 
region that interacts with Cbl-b ubiquitin ligase of host cells (Soong et al., 2008).  ExoS 
has been shown to inhibit phagocytosis (Galan & Collmer, 1999), have significant 
cytotoxic effects on epithelial tissue (Soong et al., 2008), and to regulate type III 
secretion activation upon encountering host tissue (Cisz et al., 2008).  ExoT is a 
bifunctional enzyme that also possesses an N-terminal RhoGAP domain and a C-terminal 
ADPRT domain (Shafikhani & Engel, 2006).  ExoT has been shown to be cytotoxic to 
epithelial tissue (Galan & Collmer, 1999; Shafikhani et al., 2008) and target epithelial 
healing by disrupting cytokinesis through its ADPRT domain (Shafikhani & Engel, 
2006).  ExoU is a phospholipase that has been shown to cause cytotoxicity and induce 
pro-inflammatory host reactions leading to tissue infiltration and colonization (Galan & 
Collmer, 1999; Cuzick et al., 2006; Shafikhani & Engel, 2006).  ExoY is an adenylate 
cyclase that has been shown to distort the actin cytoskeleton of host cells through its 
adenylate cyclase activity, expanding colonization (Cowell et al., 2005; Shafikhani & 
Engel, 2006).  ExoS and ExoT have also been shown to disrupt actin cytoskeletal 
structure and infiltrate host tissue through the use of their RhoGAP domains (Cowell et 
al., 2005).  A more recent study demonstrates that ExoS, T, and Y can disrupt host 
epithelium by interactions with cytoskeletal tight junctions, actin binding proteins, and 
actin (Cowell et al., 2005; Soong et al., 2008).  Another recent study has demonstrated 
that cystic fibrosis lung infections typically possess P. aeruginosa strains that tend to 
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express ExoS, while blood samples from individuals with P. aeruginosa bacteremia tend 
to express ExoU (Wareham & Curtis, 2007).   
 
4.  Non-Proteinaceous Secreted Factors 
Alginate   
In addition to exolipid compounds, P. aeruginosa also secretes an extracellular 
polysaccharide called alginate.  The virulence of alginate is functionally characterized by 
its role in the lung tissue of cystic fibrosis patients, where it is alters the P. aeruginosa 
phenotype from a non-mucoid to a mucoid colonial environment.  The release of alginate 
turns the respiratory tract into a mucoid colonized environment, which leads to promotion 
of further colonization and biofilm formation.  As neutrophils are attracted and 
accumulate at the site of infection, their own elastase, along with various excreted 
Pseudomonas cytotoxins, lead to a synergistic scenario of lysed host tissue, which in turn, 
contributes to the composition of the mucoid biofilm matrix (Amitani et al., 1991; Allen 
et al., 2005).  Interestingly, hydrogen peroxide release by neutrophils has been shown to 
increase transition of P. aeruginosa to a mucoid phenotype (Mathee et al., 1999).  
Alginate and associated biofilm matrix, in conjunction with the characteristic CFTR gene 
aberration of cystic fibrosis, responsible for excess mucus build up in the respiratory 
tract, manifests a fatal scenario of insufficient clearance, respiratory failure, and 
subsequent asphyxiation (Cystic Fibrosis Foundation). A recent study, utilizing a mouse 
model, suggests that alginate secretion increases host pro-inflammatory responses, 
leading to tissue damage and subsequent inability of the host to clear P. aeruginosa from 
the sight of infection (Song et al., 2003; Remminghorst & Rehm, 2006).   Although 
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alginate, alone, does not appear to cause tissue damage (Abusriwil & Stockely, 2007), it 
has been shown to interfere with polymorphonuclear cell chemotaxis and subsequent 
clearing mechanisms (Cabral et al., 1987; Krieg et al., 1988; Jensen et al., 1990; 
Pedersen et al., 1990; Leid et al., 2005).   
 
Rhamnolipids 
During colonization P. aeruginosa secretes two hemolytic biosurfactants called 
rhamnolipids (monorhamnolipid and dirhamnolipid) that have been shown to disrupt the 
function and facilitate cellular infiltration of human respiratory epithelial cells as a 
virulent physiological process (McClure & Schiller, 1992; Pamp and Tolker-Nielsen, 
2007; Zullianello et al., 2006).  Although both rhamnolipids appear to have cytolytic 
capabilities, dirhamnolipid has been shown to be the more virulent of the two.  
Specifically, dirhamnolipid has been shown to induce more cellular membrane disruption 
and lysis of human monocyte-derived macrophages (McClure & Schiller, 1992).   It has 
been suggested that this disruption and lysis occurs as a result of rhamnolipid 
intercalation between phosphatidylcholine molecules of the membrane’s lipid bilayer 
(Ortiz et al., 2006).   
 
Pyocyanin  
As mentioned earlier, pyocyanin serves as a virulence factor by activating harmful 
reactive oxygen species (O'Malley et al., 2003).  Reactive oxygen species are oxygen 
ions or oxygen-containing molecules whose oxygen atom has lost an electron.  With the 
loss of an electron, this oxygen species becomes highly reactive with neighboring atoms 
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in an attempt to gain back that lost electron to form a complete electron-shell 
configuration.  Reactive oxygen species cause damage when they interact with the atoms 
of macromolecules, such as nucleic acids, lipids, and proteins, of host origin, disrupting 
their structures and functions.  Pyocyanin has been shown to induce tissue damage by 
necrosis in mice with P. aeruginosa lung infections (Lau et al., 2004).  Additionally, 
more recent evidence demonstrates the ability of pyocyanin to impair acute inflammatory 
responses by activating neutrophil apoptosis (Allen et al., 2005).   
 
Hydrogen Cyanide  
 P. aeruginosa uses a cyanide synthase enzyme to convert glycine to CO2 and 
hydrogen cyanide (HCN) under low oxygen and high cell densities approaching 
stationary phase (Castric, 1975; Castric, 1977; Castric et al., 1979; Castric, 1983; Castric, 
1994).  Induction of the cyanide synthase operon  (hcnABC) has been shown to be under 
regulation by an anaerobic regulator of arginine deiminase and nitrate reductase (ANR), 
and the two quorum sensing pathways, las and rhl (Pessi & Haas, 2000).  HCN is an 
extremely cytotoxic compound because it readily ionizes, freeing cyanide, which directly 
inhibits the function of cytochrome c oxidase (Jones et al., 1984; Jensen et al., 1984).  
Aerobic cellular respiration relies on this enzyme to transfer electrons to oxygen in the 
last step of the electron transport chain, producing energy in the form of ATP.  In 2001, 
Gallagher and Manoil demonstrated the lethal effects of hydrogen cyanide production by 
P. aeruginosa in C. elegans (Gallagher & Manoil, 2001).  Specifically, they showed that 
a hydrogen cyanide synthase (hcnC) null strain was unable to cause lethal infection 
(Gallagher & Manoil, 2001).  Most recently, the virulent effects of hydrogen cyanide 
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production has been assessed in humans.  In 2008, Ryall et al. examined P. aeruginosa 
infected lung tissue of cystic fibrosis and non-cystic fibrosis bronchiectasis patients and 
were able to show cyanide ion accumulation and subsequent decrease in lung function 
(Ryall et al., 2008).   
 
5.  Surface Structures  
Flagella  
  P. aeruginosa has a number of pathogenic features that allow motility.  One 
physiological attribute of P. aeruginosa that allows it to inhabit such diverse 
environments is the flagellum (Figure 2). The presence of a flagellum allows swimming 
motility (Mattick, 2002; Arora et al., 2006).   
 
 
Figure 2.  Microscopy image of Pseudomonas aeruginosa pilus and flagellum 
structures (Image provided by Erica Jewell).   
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Flagella are propeller-like organelles made of polymerized flagellin monomer units that 
extend indiscriminately from the cell surface.  A molecular motor is responsible for the 
kinetic propulsion of the flagellum, which results in the swimming motion (Bardy et al. 
2003; Doyle et al., 2004).  In addition to swimming motility, flagella also provide 
motility by swarming.  Swarming motility is a synchronized form of motility utilized by 
P. aeruginosa on semisolid medium.  Swarming appears to require a battery of specific 
conditions such as the presence of flagella, type IV pili, rhamnolipid production, certain 
amino acids, and a nitrogen source (Köhler et al., 2000; Caiazza et al., 2005).  These 
locomotive attributes are valuable to the microorganism for purposes of chemotaxis, 
nutrition, pathogenesis, and survival (Mahenthiralingam & Speert, 1995; Feldman et al., 
1998; Soscia et al., 2007).   
In addition to swimming and swarming motility, flagella serve P. aeruginosa as a 
bacterial adhesin.  Specifically, flagellin has been shown to have binding affinity for 
Muc1, a mucin found on respiratory epithelial cells (Arora et al., 1998; Lillehoj et al., 
2002).  Although flagellin’s ability to bind mucins may play a leading role in colony 
establishment, P. aeruginosa flagella have also been shown to be a physiological 
requirement for internalization by host phagocytic cells (Mahenthiralingam & Speert, 
1995).  In 2006, Tseng et al. published a study that demonstrated the ability of P. 
aeruginosa flagellin to induce a host innate immune response.  Flagellin was shown to 
induce the expression of NF-kappaB leading to an inflammatory response in human 
tracheal epithelium cells (Tseng et al., 2006).  A previous study of respiratory infection 
has indicated that flagella activate host inflammatory responses through epithelial cell 
toll-like receptors, TLR2 and TLR5 (Adamo et al., 2004).  Most recently, in a mouse 
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respiratory model, flagella interaction with TRL5 has been shown to be sufficient for 
induction of innate defenses (Ramphal et al., 2008).   
 
LPS and Pili  
 LPS and pili are two important virulence factors that pertain specifically to the 
current research.  Because of their fundamental application to my thesis project, they 
have each been given their own sections and discussed in depth below.     
 
 
D.  LPS  
 
1.  LPS Structure      
  Lipopolysaccharide is the primary surface structure of gram-negative bacteria.  
The LPS layer is made up of lipid A, a core oligosaccharide, and in some instances, such 
as P. aeruginosa, an O-antigen repeating unit (Figure 3).  Lipid A serves to anchor the  
 
Figure 3.  Illustration of the basic structure of LPS. 
24 
LPS complex to the outer cell membrane, while the O-antigen repeating unit is attached 
to the core oligosaccharide following assembly on an undecaprenol-phosphate molecule 
(Marolda et al., 2004; Nilsson et al., 2006).  The lipid A structure is fairly conserved 
across gram negative bacteria (Figure 4) (de Kievit & Lam, 1994).  In general, lipid A is 
synthesized in the cytoplasm through a series of anabolic steps, of which, primarily 
involve the addition of phospholipids to uridine diphosphate (UDP)-N-acetylglucosamine  
 (GlcNAc).  Lipid A is then covalently linked to two 2-keto-3-deoxyoctonate (Kdo) 
molecules and transported to the outer membrane.  The Kdo molecules serve to 
covalently link lipid A to the core oligosaccharide on the cell surface (Raetz & Whitfield, 
2002).   
 
Figure 4.  Predicted molecular structure of P. aeruginosa 1244 LPS.  Illustration 
generated by ChemDraw software (Courtesy of Dr. Joseph Horzempa).   
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The core oligosaccharide is broken into lipid A-proximal and lipid A-distal 
divisions, referred to as the inner and outer core, respectively (Figure 4).  The portion 
that forms a covalent linkage to Kdo-lipid A is referred to as the inner core and typically 
consists of Kdo, conserved L-glycero-D-manno-heptose residues, and phosphate moieties 
(de Kievit & Lam, 1994; Masoud et al., 1995; Raetz & Whitfield, 2002).  The portion of 
the core that covalently binds the O-antigen repeating unit is referred to as the outer core 
and typically consists of D-glucose, 2-amino-2-deoxy-D-galactose, L-rhamnose, and L-
alanine (Figure 4) (de Kievit & Lam, 1994; Masoud et al., 1995).  In particular, strains of 
Pseudomonas can be identified by the immunological properties of LPS O-antigens.  
Although other serotyping systems exist, P. aeruginosa strains are most commonly  
identified by the International Antigen Typing System (IATS).  The IATS is a serotyping 
system that is based on anti-sera agglutination of heat-stable P. aeruginosa O-antigens 
(Liu et al., 1983).  The LPS of P. aeruginosa is made up of two bands of O-antigens, the 
A-band and the B-band (Rivera et al., 1988; Rivera & McGroarty, 1989).  The A-band 
contains shorter, more conserved chains composed of the neutral D-rhamnan sugar, while 
the B-band consists of the diverse O-antigen repeating structures identified by the IATS 
serotyping system (Lightfoot & Lam, 1991; de Kievit & Lam, 1994; Rocchetta et al., 
1999; Raetz & Whitfield, 2002).  In P. aeruginosa 1244, it appears that the B-band O-
polysaccharides are derived from central metabolic pathways such as the pentose 
phosphate cycle and glycolysis.   
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2.  O-Antigen Biosynthesis     
The general steps of O-antigen subunit biosynthesis are known for P. aeruginosa 
1244 (Figure 5).  The serotype O7 gene cluster was structurally elucidated by Raymond 
et al. in a 2004 publication identifying multiple O-antigen loci in P. aeruginosa  
 
Figure 5.  General steps of O-antigen subunit biosynthesis in P. aeruginosa 1244.  
The gene products known to function in this pathway are in red.   
 
(Raymond et al., 2002).  The gene product of wbpM serves as a bifunctional UDP-
GlcNAc C6 dehydratase/C4 reductase.  This reductase mediates the formation of UDP-N-
acetyl-D-quinosamine (QuiNAc) which is the nucleotide precursor of the first O-antigen 
sugar residue, UDP-β-D-N-acetylfucosamine (FucNac).  UDP-QuiNAc is derived from 
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UDP-GlcNAc, which most likely exists as a downstream metabolite of fructose-6-
phosphate from the pentose phosphate pathway (Kneidinger et al., 2003; Druzhinina et 
al., 2005).  The gene product of wbpL encodes a bifunctional glycosyltransferase that 
subsequently transfers the FucNAc sugar residue from the UDP-FucNAc nucleotide 
precursor to an undecaprenol-phosphate molecule in the inner cell membrane 
(DiGiandomenico et al., 2002).  As mentioned earlier, DiGiandomenico et al. showed 
that PA1244 wbpM and wbpL mutants lacked the ability to produce the LPS O-antigen 
repeating unit.  The remaining two sugar residues (Xylose and Pseudaminic acid) are 
added onto the inner membrane embedded undecaprenol-phosphate (Und-P) facing the 
cytoplasm.  UDP-xylose is a derivative of UDP-glucuronic acid (GlcUA), which is a 
known metabolite of glycolysis (Harper & Bar-Peled, 2002; Seifert, 2004; Hung et al., 
2007).  Interestingly, UDP-GlcUA, along with mannuronic acid, serve as key 
components in the production of alginate (Hung et al., 2007).  As UDP-FucNAc, UDP-
5NβOHC47NPse is also a derivative of UDP-GlcNAc thought to have derived from 
fructose-6-phosphate of the pentose phosphate cycle (Goon et al., 2003).  Each sugar 
residue is sequentially transferred to undecaprenol-phosphate as a linked nucleotide UDP 
precursor.  Once all three sugar residues are added to undecaprenol-phosphate (now 
undecaprenol-pyrophosphate+FucNAc+Xyl+5NβOHC47NPse), a Wzx flipase enzyme is 
required to position the Und-PP/O-antigen complex in the outer leaflet of the inner-cell 
membrane, facing the periplasm.  A study by Marolda et al. published in 2004, 
demonstrated that Wzx flipase activity, in Salmonella, occurs through recognition of the 
primary Und-PP sugar residue.  Once the Und-PP/O-antigen complex has been flipped to 
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the outer leaflet of the inner membrane by Wzx, the repeating unit enters one of two 
pathways discussed below.   
 
3.  O-Antigen Polymerization 
With regards to the formation and addition of the LPS O-antigen repeating unit to 
the core oligosaccharide, the gene products required at each step have been well 
characterized (Figure 6).  For the LPS, once the O-antigen is flipped to the periplasm by 
Wzx flipase, Wzy is responsible for O-antigen polymerization (Marolda et al., 2004).  
Once polymerized by Wzy, Wzz regulates the final O-antigen chain length.  Once the 
proper repeating unit is synthesized, WaaL functions as a ligase to link the O-antigen 
repeat unit to the core oligosaccharide (Abeyrathne et al., 2005).   
The mechanism by which LPS is translocated from the site of assembly (inner 
membrane) to its final destination (surface of the outer membrane) is less understood in 
P. aeruginosa.  The most knowledge about this process has been obtained from studies in 
E. coli (Tefsen et al., 2005; Sperandeo et al., 2007; Ruiz et al., 2008).  In E. coli, it has 
been suggested that an ABC transporter, LptBFG, uses energy to remove LPS from the 
inner membrane en route to the outer membrane (Sperandeo et al., 2007; Ruiz et al., 
2008).  However, the question still remains as to how LPS transverses the periplasmic 
space to contact the outer membrane.  Two possible scenarios have been proposed.  One  
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Figure 6.  General steps of LPS O-antigen polymerization in P. aeruginosa 1244.  
The gene products known to function in this pathway are in red.    
 
scenario suggests that a periplasmic chaperone, LptA in E. coli, transports LPS to the 
outer membrane (Sperandeo et al., 2007; Ruiz et al., 2008).  The second scenario 
suggests that LPS reaches the outer membrane through direct inner membrane-outer 
membrane contact sites, possibly mediated by a protein intermediate (Tefsen et al., 
2005).  Once in contact with the outer membrane, proteins LptD and LptE are believed to 
finalize the orientation the LPS at the surface of the outer membrane (Bos et al., 2004; 
Wu et al., 2006; Ruiz et al., 2008).   
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4.  LPS Virulence    
  As introduced earlier, one of the major virulence factors of P. aeruginosa is the 
outer membrane bound LPS layer.  This virulence is attributed to LPS inhibition of host 
cell communication and the ability to adhere to various surfaces, such as lung tissue (Yeh 
et al., 2005; Pier, 2007).  Recent research on LPS virulence demonstrates that LPS of P. 
aeruginosa serotype 10 decreases the expression of nasal epithelial cell signaling protein, 
connexin 43, which suggests LPS may play a role in diminishing host cell signaling and 
the promotion of P. aeruginosa colonization (Yeh et al., 2005).  LPS core has also been 
shown to be a potential ligand for the epithelial-expressed CFTR protein, which as 
mentioned above, has a paradoxical immune effect dependent on the target organ (Zaidi 
et al., 1996; Lyczak et al., 2000).  Adhesive properties of LPS contribute, along with 
flagella and pili, to P. aeruginosa colony establishment.  In addition to LPS binding to 
the CFTR protein, it has also been shown to have affinity for gangliotetraosylceramide, a 
glycolipid expressed by corneal cells (Gupta et al., 1994).  LPS, along with another 
virulence factor, exotoxin A, has been shown to increase the production of interferon 
regulatory factor 1 (IRF-1), which mediates an inflammatory response, in pulmonary 
infections (Weiland et al., 2002).  This has significance to cystic fibrosis patients, which 
often have been shown to have decreased IRF-1 production (Weiland et al., 2002).  A 
recent study utilizing a mouse respiratory model demonstrated that an LPS-induced 
innate immune response was primarily mediated through TLR4 (Ramphal et al., 2008).   
Recent evidence suggests that optimization of the virulent potential of P. 
aeruginosa is regulated, in part, by the lengthening of the O-antigen repeating unit chain 
(Kintz et al., 2008).  Complete loss of the O-antigen has been shown to increase 
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susceptibility to clearance by host serum (Rocchetta et al., 1999; Priebe et al., 2004).  
Interestingly, as mentioned earlier, once biofilm colonization has been established, P. 
aeruginosa is found to have reduced or lost LPS O-antigen expression, promoting 
evasion of innate immune responses (Rocchetta et al., 1999).   
 
 
E.  Type IV Pili  
 
1.  Pilin   
 In general, type IV pili (Tfp) have been identified in a variety of gram positive 
and gram negative bacteria. Type IV pili are bundled, rod-like extensions located at one 
or both ends of the cell that are composed of helically arranged pilin subunits (Touhami 
et al., 2006).  Generally, these strong, yet flexible, filaments can reach 3-4 µm in length 
and have a diameter of 6 nm (Mattick et al., 1996; Maier et al., 2002; Craig et al., 2003).  
Type IV pili can be subdivided into two groups, TfpA and TfpB.  These two subgroups 
are mainly based on signal peptide length and mature peptide length (Craig & Li, 2008; 
Pelicic, 2008).  TfpA pilins have leader peptide sequences typically 10 amino acids or 
less, and a mature peptide sequence of about 150-160 amino acids (Pelicic, 2008).  TfpB 
pilins typically have peptide leader sequences between 15-30 amino acids and mature 
protein sequences at an extreme maximum of 180-200 amino acids or extreme minimum 
of 40-50 amino acids (Pelicic, 2008).  Both subgroups of Tfp have the same general 
structural features consisting of a homologous hydrophobic N-terminal α-helical tail and 
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a globular head containing an anti-parallel β-sheet arrangement and a conserved C-
terminal disulfide loop region (Figure 7) (Craig & Li, 2008; Pelicic, 2008).   
 
Figure 7. Homology model of the tertiary structure of PA1244 PilA protein.   
 
 The α-helical tail and the disulfide loop region play important roles in pilus 
functionality.  The N-proximal 25-30 residues of Tfp are highly conserved across various 
bacterial species (Castric & Deal, 1994; Craig et al., 2003; Pelicic, 2008).  Structural 
analysis of pilin subunits from Neisseria gonorrhoeae, N. meningitidis, P. aeruginosa, 
and Vibrio cholerae have demonstrated that N-terminal α-helix interactions mediate pilus 
assembly and resulting hydrophobicity of the filament core (Parge et al., 1995; Craig et 
al., 2003; Helaine et al., 2007; Li et al., 2008).  Although there is sequence dissimilarity 
within the disulfide loop regions of pilin groups, this region has been shown to function 
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in adhesion and immunogenicity (Lee et al., 1989; Castric & Deal, 1994; Lee et al., 1994; 
Comer et al., 2002; Giltner et al., 2006).   
  P. aeruginosa possess TfpA which can be further subdivided into five groups, 
Groups I-V (Castric & Deal, 1994; Kus et al., 2004).  These five groups are based on 
varying primary sequence characteristics, antigenicity, and the presence or absence of 
defined or undefined accessory proteins (Castric & Deal, 1994; Kus et al., 2004).  The 
current research works with Groups I, II, and III.  PA1244 possesses Group I Tfp, while 
the most common lab strains, such as PAK, PA103, and PAO1, possess Group II Tfp.  
Group I pilins tend to be more conserved, have a higher GC content, have a larger gene 
sequence, and possess the pilO accessory protein gene in between the pilA gene and the 
tRNAThr sequence in the operon (Castric & Deal, 1994; Kus et al., 2004).  Group II pilins 
have shorter gene sequences than Groups I and III, and do not contain an additional open 
reading frame between the pilA and tRNAThr sequences (Castric, 1995; Kus et al., 2004).  
Group III pilins have longer gene sequences than either, Group I or Group II, pilins (Kus 
et al., 2004).  Group III pilins also possess the open reading frame of an accessory protein 
of unknown function, TfpY, between the pilA and tRNAThr sequences (Kus et al., 2004).  
Figure 8, below, provides a basic illustratation of the pilin biosynthetic operon of Groups 
I, II, and III.   
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Figure 8.  Operon differences between Type IV Pilin Groups I, II, and III (adapted from 
Kus et al., 2004).   
 
2.  Pilin Polymerization 
The current model for pilin polymerization is based on studies conducted on 
enteropathogenic E. coli (EPEC), N. gonorrhoeae, and Myxococcus xanthus pilus 
formation (Craig et al., 2006; Craig & Li, 2007; Jakovljevic et al., 2008; Pelicic, 2008).  
This model requires the presence of a cytoplasmic membrane associated protein (BfpD in 
EPEC, PilF in N. gonorrhoeae, PilB in P.aeruginosa and M. xanthus), an inner 
membrane protein (BfpE in EPEC, possibly PilG in N. gonorrhoeae, and possibly PilC in 
P. aeruginosa), and mature pilin (Figure 9) (Burrows, 2005; Craig et al., 2006; Craig & 
Li, 2007; Jakovljevic et al., 2008; Pelicic, 2008).  The Sec machinery is responsible for  
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prepilin translocation to the inner cell membrane.  Once in the cytoplasmic membrane, 
the PilD endopeptidase is responsible for the cleavage of prepilin’s basic leader sequence 
(~6-7 amino acids) and N-methylation of the resulting membrane bound pilin subunit, 
producing mature pilin (Strom & Lory, 1992).  Mature pilin can then be pooled in the 
membrane and recruited for polymerization.  Recruitment to the site of polymerization 
may partially result from free pilin interactions with the hydrophobic tails of recently 
polymerized pilins (Craig & Li, 2007).  The pilus has been shown to be composed of 3 
strands of pilin subunits arranged in a helix.  At the site of polymerization, pilin subunits 
are added one at a time to each strand.   
 The motor ATPase, PilB, is thought to interact with an inner membrane protein, 
potentially PilC, or a complex of unidentified proteins to form a scaffold for subsequent 
polymerization.  Once a pilin molecule docks this protein scaffold via attraction to pilin 
already added to the pilus, hydrolysis of ATP to ADP by PilB causes the inner membrane 
protein to change conformation.  This conformational change acts as a molecular piston 
to punch the pilus upward into the periplasm about 10 Å, leaving room for a new pilin 
molecule to be recruited (Craig et al., 2006; Craig & Li, 2007; Jakovljevic et al., 2008; 
Pelicic, 2008).  PilB exchanges ADP for ATP causing the inner membrane protein to shift 
back to its resting conformation, starting the polymerization process all over again 
(Burrows, 2005; Craig et al., 2006; Craig & Li, 2007; Jakovljevic et al., 2008; Pelicic, 
2008).  As pilin monomers are added, the pilus bundle is extruded into the extracellular 
space through the pore forming, PilQ, protein in the outer cell membrane (Figure 9) 
(Martinez et al., 1998).  Although, the role of PilC as the inner membrane protein  
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Figure 9.  Illustration of the general protein machinery responsible for the 
production of a type IV pilus (adapted from Mattick, 2002).   
 
providing piston function has not been demonstrated, PilC has been shown to interact 
with PilB through a cytoplasmic domain at the membrane periphery and is required for 
PilB polar localization in P. aeruginosa (Burrows, 2005).   
 Craig et al. has suggested the reversal of this model for pilin depolymerization, by 
switching from PilB polymerizing ATPase to PilT depolymerizing ATPase through 
interaction with the inner membrane protein (Craig et al., 2006; Craig & Li, 2007).  
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Although PilC has also been suggested to interact with PilT at the cytosolic membrane 
periphery, no evidence exists to demonstrate the ability of PilC to function as a 
macromolecular piston (Burrows 2005).  PilU has been shown to support retraction by an 
unknown mechanism, but has also been shown to be a cytosolic membrane associated 
ATPase, ruling out its role as an inner membrane protein or periplasmic effector 
(Graupner et al., 2001; Chiang et al., 2005; Chaing et al., 2008).  In P. aeruginosa, 3 
ATPase hexamers (PilB, PilT, PilU) have been shown to play a role in pilin 
polymerization/depolymerization (Burrows, 2005; Chiang et al., 2008).  Studies in P. 
aeruginosa, P. stutzeri, N. meningitidis, and M. xanthus have demonstrated these 
hexamers to be cytosolic membrane associated proteins (Pujol et al., 1999; Chiang et al., 
2005; Jakovljevic et al., 2008).  Chaing et al. pointed out that P. aeruginosa PilB, PilT, 
and PilU do not have known transmembrane domains or periplasmic signal sequences 
(Chiang et al., 2005), supporting this current “motor-piston” model’s need for one or 
more proteins to transverse the membrane into the periplasmic space and transfer the 
chemical energy from ATP hydrolysis into  mechanical energy for pilus 
assembly/disassembly.   
 Taking into account the uncertain identity of ATPase associated effector proteins, 
an alternate model has been proposed by studies of PilT and PilB in M. xanthus.  In this 
model, pilin molecules assemble into a pilus spontaneously, whereby PilB and PilT serve 
as direct molecular motors or regulators of pilin polymerization/depolymerization 
(Jakovljevic et al., 2008).  In either model, it is clear that cytosolic ATP is required for 
PilB and PilT to mediate pilus assembly/disassembly (Jakovljevic et al., 2008).   
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3.  Pili Virulence  
As opposed to the flagellum of P. aeruginosa, which mediates swimming 
motility, the presence of type IV pili allows twitching motility (Mattick, 2002; Arora et 
al., 2006).  Figure 2, above, illustrates pilus and flagellum structures of P. aeruginosa.  
The motion generated by twitching motility results from depolymerization-
polymerization of pilin subunits (Touhami et al., 2006).  Type IV pili also serve 
additional functions for P. aeruginosa, such as adherence to moist, solid surfaces and 
colony formation (Mattick, 2002; Kim et al., 2006).  As an adhesin, pili has been shown 
to bind to abiotic surfaces such as stainless steel, plastics, glass, and various minerals, as 
well as biotic surfaces such as human epithelial cells, red blood cells, other bacteria, 
fungi, and yeast (Woods et al., 1980; Gupta et al., 1994; Mattick, 2002; Giltner et al., 
2006; Touhami et al., 2006).  It has been estimated that pilus-mediated adhesion accounts 
for about 90% of the attachment capabilities of P. aeruginosa (Hahn, 1997).   
Recent findings suggest that the glycosylation of pili and flagellum is an optimal 
virulence enhancing attribute of P. aeruginosa pathogenicity (Kus et al., 2004; Smedley 
et al., 2005; Arora et al., 2006).  In particular, Smedley et al. found that the glycosylated 
type IV pili are more commonly found than non-glycosylated pili in clinical isolates 
(about 67% in sputum samples), while Kus et al. has shown that glycosylated pili were 
most common among clinical isolates obtained from cystic fibrosis patients (about 67%) 
(Kus et al., 2004; Smedley et al., 2005).  Specifically, Smedley et al. were able to 
demonstrate increased virulence of glycosylated pili by showing that a strain producing 
glycosylated pilin, PA1244, significantly outcompeted a non-glycosylated pilin 
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producing strain, 1244G7, for survival in a mouse respiratory model (Smedley et al., 
2005).   
The ability of virulence factors to evade an acquired (memory) immune response 
is what dictates the severity of pathogenicity.  However, recent evidence demonstrates 
that the hypervariable regions of N. gonorrhoeae type IV pili serve as antigenic epitopes 
for recognition by host memory eliciting T lymphocytes (Hansen et al., 2007; Plant & 
Jonsson, 2006).   This information, along with recent findings on pilin glycosylation in P. 
aeruginosa 1244 (Horzempa et al., 2008), holds the potential for microbiological vaccine 
production. 
 
 
F.  Glycosylation of Pseudomonas aeruginosa 1244 Pilin  
 
1.  Characterization of Pilin Glycan  
P. aeruginosa 1244 belongs to the IATS serotype O7.  As mentioned earlier, 
IATS is a method of P. aeruginosa strain identification based on specified anti-sera 
agglutination of heat-stable, surface O-antigens (Liu et al., 1983).  The O7 LPS O-antigen 
is characterized by the presence of three sugar residues, 5NβOHC47NFmPse, Xyl, and 
FucNAc.  In 2001, Castric et al. published results that characterized the PA1244 pilin 
glycan (Figure 10).   
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Figure 10.  PA1244 pilin aminoglycan produced by total pilin digestion (Castric et 
al., 2001).  
 
Castric et al. showed that the pilin aminoglycan (α-5NβOHC47NFmPse-(2Æ4)-β-Xyl-
(1Æ3)-β-FucNAc-(1Æ3)-Ser) was covalently attached to a serine residue and possessed 
the same sugar residues as the LPS O-antigen (5NβOHC47NFmPse, Xyl, FucNAc) 
(Castric et al., 2001).  In 2002, Comer et al. demonstrated that the C-terminal 148 serine 
residue of a pilin monomer serves as the sole attachment site for the O-antigen repeating 
unit (Comer et al., 2002).  In a separate study published by the Castric lab in 2002, 
DiGiandomenico et al. showed that PA1244 deletion mutants of wbpM, responsible for 
synthesis of the first sugar (FucNAc) of the O-antigen, and wbpL, responsible for the 
transfer of the first sugar to an undecaprenol phosphate carrier, were not able to produce 
the LPS O-antigen repeating unit, nor glycosylated pilin.  These findings demonstrate that 
the pilin glycan and the LPS O-antigen are produced by the same biosynthetic pathway 
(DiGiandomenico et al., 2002).  The glycan/O-antigen repeating unit is preassembled on 
an undecaprenol phosphate carrier lipid within the cytoplasm, transported to the inner cell 
membrane, and then transferred to pilin or LPS core within the periplasm.  This pathway 
is demonstrated in Figure 11.   
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Figure 11.  Proposed pathway for pilin glycosylation.   The gene products known to 
function in each pathway are in red.    
 
2.  Glycosylation Pathway  
For pilin glycosylation, once Wzx has flipped the O-antigen to the periplasmic 
space, prepilin must also be present in the inner cell membrane (Figure 11).  Once the 
prepilin subunit is targeted to the inner cell membrane via the Sec machinery it undergoes 
posttranslational modification by cleavage of its basic leader sequence and N-methylation 
by PilD (Strom & Lory, 1992).  PilO is responsible for the addition of the O-antigen 
glycan to pilin in the periplasm (Smedley et al., 2005; Qutyan et al., 2007).  PilO 
transfers the O-antigen repeating unit from Und-P to pilin through the recognition of the 
O- antigen’s primary sugar moiety, β-D-FucNAc, similar to Wzx flipase recognition of 
the O-antigen-Und-P complex (Marolda et al., 2004; Horzempa et al., 2006b).    
In pilus formation, a PilBC complex located in the inner cell membrane is 
responsible for polymerization of the pilin subunits, while PilT depolymerizes pilin 
42 
subunits.  PilQ forms a pore in the outer membrane whereby polymerized pilin subunits 
are channeled out of the cell forming a pilus (Figure 9) (Martinez et al., 1998). 
As mentioned earlier, the pilin subunits that form the pilus are arranged helically 
by interactions between the alpha-helix tails and the globular head groups of the 
monomers.  This arrangement shields functionally conserved regions of the PilA 
sequence, while exposing post-translational modifications (such as glycosylation) and 
hypervariable regions (Craig et al., 2006).  Surface exposure of hypervariable regions and 
modifications, such as glycosylation, have been shown to play an important role in P. 
aeruginosa pathogensis and immunogenicity (Smedley et al., 2005; Hansen et al., 2007).   
 
3.  Characterization of PilO 
 As mentioned earlier, P. aeruginosa 1244 possesses group I pilin (Castric & Deal, 
1994).  In 1995, Castric identified the open reading frame of an accessory protein 
between the pilA and tRNAthr gene sequences in the group I operon of P. aeruginosa 
1244, which was named pilO and shown to be required for PA1244 pilin glycosylation 
(Castric, 1995).  Specifically, Castric showed that recombinant pilA, overexpressed in a 
pilAO mutant, PA1244N3, was not able to produce pilin that could be recognized by a 
sugar specific reagent (Castric, 1995).  Later studies have further supported the necessity 
of pilO in the glycosylation of pilin.  In 2002, DiGiandomenico et al. showed that a strain 
of P. aeruginosa that does not contain the pilO ORF, PA103, could produce 
heterologously expressed PA1244 pilin glycosylated with native O-antigen repeating unit 
(serotype O11) upon introduction of recombinant pilO (DiGiandomenico et al., 2002).  In 
2005, Smedley et al. constructed a true pilO delete strain, PA1244G7, which produced 
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endogenous pilin that could not be recognized with a sugar-specific antibody (Smedley et 
al., 2005).  Collectively, these findings suggest that PilO is the only protein necessary for 
the covalent linkage of the O-antigen repeating unit to pilin.   
 PilO has a predicted molecular weight of 51,000 kDa that has recently been 
shown to localize to the inner cell membrane (Qutyan et al., 2007).  As a member of the 
Wzy_C family, PilO shares similarity in size, number of predicted transmembrane 
regions, and position of the Wzy_C domain with two other proteins of the Wzy_C family, 
Wzy and WaaL, responsible for the transfer of O-antigen repeating units from an 
undecaprenol-phosphate carrier molecule to a substrate in the periplasmic space 
(Bateman et al., 2004; Qutyan et al., 2007).  Through a series of single amino acid 
deletions/alterations, Qutyan et al. was able to demonstrate that the catalytic regions of 
PilO lie within the Wzy_C domain and C-proximal 430-461 residues.  Qutyan et al. then 
went on to show PilO topology at the inner cell membrane, through a series of PilO 
fusions to cytoplasmic LacZ and periplasmic PhoA, which identified the periplasmic 
location of the catalytic regions (Figure 12) (Qutyan et al., 2007).   
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Figure 12.  Topology of PilO.  Qutyan et al. determined the catalytic regions to be 
located in the periplasm, within the Wzy_C domain (consensus residues 281-301) and the 
C-proximal hydrophilic region (residues 430-461).  The white circles and black diamonds 
are amino acid residues.  Figure from Qutyan et al., 2007.     
 
4.  Specificity of the Glycosylation Reaction  
 Once pilin is embedded in the cytoplasmic membrane, covalent glycan linkage to 
the C-terminal 148 serine residue may occur through the catalytic domain of PilO within 
the periplasmic space.  As mentioned, the pilin glycan and the O-antigen repeating unit 
consist of the same three saccharides from the same biosynthetic pathway 
(DiGiandomenico et al., 2002).  P. aeruginosa 1244 strains containing deletions in either 
wbpM or wbpL resulted in the absence of both, glycosylated pilin and O-antigen 
polymerization (DiGiandomenico et al., 2002).  These findings also suggest that the O-
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antigen repeating unit and pilin glycan are preassembled on, and subsequently transferred 
from, an undecaprenol phosphate carrier molecule.   
DiGiandomenico et al. demonstrated the low glycan substrate specificity of the 
glycosylation reaction by separately expressing the O-antigen biosynthesis gene clusters 
of PA103 and E. coli O157 in PA1244 and recovering pilin glycosylated with the 
heterologous glycans (DiGiandomenico et al., 2002).  Horzempa et al. further addressed 
the issue of low glycan specificity in a 2006 publication in which a strain of PA103 that 
was deficient in the addition of the second sugar (Xyl) of the trisaccharide O-antigen 
repeating unit, in the presence of PA1244 pilAO, produced pilin glycosylated with only 
the first sugar (FucNAc) of the glycan (Horzempa et al., 2006b).  These results in 
combination with comparative structural similarities of several reducing end O-antigen 
saccharides of various P. aeruginosa strains indicated that recognition of the glycan 
substrate lies solely in the reducing end moiety (Horzempa et al., 2006b).   
In 2001, Castric et al. identified a serine residue as the site of glycan linkage to 
pilin (Castric et al., 2001)  In 2002, Comer et al. showed that only the 148 serine residue 
of pilin accepted a glycan (Comer et al., 2002).  Further examination by Horzempa et al. 
in 2006 suggested that a terminal serine residue, in combination with a compatible 
surface charge, is the sole pilin specific recognition structure for PilO-mediated O-
linkage of a glycan (Horzempa et al., 2006a).  To arrive at this conclusion, Horzempa et 
al. tested the glycosylation status of a series of mutant PA1244 and PA103 pilins.  Site-
directed mutagenesis of DSL cysteine residues to alanines permitted glycosylation of 
PA1244 pilin.  Deletions of several segments of the DSL permitted glycosylation of 
PA1244 pilin.  Insertion of 5 residues with an overall positive charge into the negatively 
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charged DSL of PA103 pilin with a C-terminal serine permitted glycosylation in a pilAO 
null strain, PA1244.47, upon complementation with pilO.  Extension of a C-terminal 
serine away from the electronegative DSL of PA103 pilin with a tail of alanine residues 
permitted glycosylation in PA1244.47 upon complementation with pilO (Horzempa et 
al., 2006a).   
 
 
G.  Market Potential of PA Vaccination  
P. aeruginosa is a lethal pathogen to immunocompromised individuals and 
patients suffering from chronic respiratory disease or injuries.  Commonly affected are 
those suffering from Cystic Fibrosis, Chronic Obstructive Pulmonary Disease (COPD), 
cancers, immunodeficiency disorders, AIDS, and severe burns.  Conjugate vaccine 
technology holds the potential to provide preventative treatment against Pseudomonas 
infections.  A conjugate vaccine covalently links a memory eliciting antigen to a weaker 
or non-memory inducing antigen.  Typically, as in the case of the P. aeruginosa vaccine, 
a non-memory inducing surface glycan (sugar of LPS) is linked to a memory inducing 
protein (pilin or toxoid), thereby mediating a memory response to the LPS surface 
glycan-coat of a gram-negative bacterium.  Dr. Peter Castric of Duquesne University has 
designed a P. aeruginosa glycoconjugate vaccine, which enables conjugate vaccination 
antigens to be manufactured in vivo.  In other words, the pathogen itself becomes a 
biological production factory of the vaccine.  Dr. Castric’s technology takes advantage of 
P. aeruginosa’s physiological mechanism of providing glycosylated pilin to produce 
covalently linked virulence factors that can function as vaccine components.   
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Dr. Castric’s P. aeruginosa biconjugate vaccine provides immunization against P. 
aeruginosa by stimulating a T-dependent response, in turn, leading to a memory response 
against the LPS O-antigen surface layer of this gram-negative bacterium.  This extremely 
antigenic LPS O-antigen layer is readily recognized by the immune system, yet is 
recognized by a T-independent response.  This means no memory.  When your body 
establishes memory to a pathogen, it stores up immune information that will allow your 
body to provide you with long term protection against that pathogen.  The P. aeruginosa 
vaccine technology is permissive of immune memory by covalently linking the LPS O-
antigen to the pilin protein.  This is the basic idea behind all current glycoconjugate 
vaccines.  The pilin protein appears ideal for glycoconjugation because it has previously 
been shown to elicit a memory response (Ohama et al., 2006), which suggests the ability 
to confer this memory on the covalently linked glycan subunit (Lesinski & Westerink, 
2001).  In 2008, Horzempa et al. showed that pure glycosylated PA1244 pilin provided 
protection against a PA1244 LPS-producing mutant that lacked pilus formation in mouse 
pneumonia and burn models (Horzempa et al., 2008).  Although this study only qualifies 
as preliminary animal work, glycoconjugate vaccines have been shown to provide long-
term protection in humans.  In 2005, Robbins et al. demonstrated their H. influenzae type 
b capsular polysaccharide-tetanus toxin conjugate vaccine provided protection after 9 
years following initial administration (Claesson et al., 2005).  Other systems have used 
LPS O-antigens linked to various bacterial proteins such as toxoids (i.e. inactive forms of 
bacterial toxins from diphtheria or tetanus) (Crowcroft, 1999).  Dr. Castric is currently 
using his own technology to explore the application of vaccination design against other 
pathogenic gram-negative bacteria, such as E. coli O157, the cause of travelers’ diarrhea 
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and Jack-in-the-Box disease.  In the case of E. coli O157, the technology uses P. 
aeruginosa to covalently attach the glycan of O157 to P. aeruginosa pilin.   
 P. aeruginosa is a leading cause of lung infections in Cystic Fibrosis patients and 
nosocomial pneumonia infections.  With respect to these pathological threats, the 
commercial opportunity of the P. aeruginosa biconjugate vaccine has modest to globally-
intense potential.  Cystic Fibrosis is a genetic disorder manifested from a mutation in the 
CFTR gene.  The CFTR gene encodes the CFTR protein, that when defective, effects 
cellular transport of charged particles resulting in improper mucus production.  This 
mucus is not easily cleared from the body, which allows it to build up and cause serious 
health problems.  Cystic Fibrosis is estimated to effect over 30,000 people in the United 
States (1:31 Americans) (Wertz et al., 1991; Cystic Fibrosis Foundation, 2009). 
Moreover, greater than 90% of deaths in Cystic Fibrosis patients result from P. 
aeruginosa infections (Corech et al., 2005).  
 Additionally, P. aeruginosa is one of the four most common gram-negative 
pathogens responsible for nosocomial infections according to the CDC (Weinstein, 
1998).  P. aeruginosa’s ubiquitous inhabitance and increased resistance to metallo-β-
lactamase antibiotics has made P. aeruginosa a grave threat to those with compromised 
immune systems (Zavascki et al., 2006).  Statistically, it has been reported that P. 
aeruginosa is responsible for 10% of nosocomial tissue infections and 20% of 
nosocomial pneumonia infections (Beatty et al., 2005; Matar et al., 2005).  Although the 
acquisition of reliable statistics on the incidence of mortality from P. aeruginosa 
infection was unattainable due to reliability issues, the reported lethality in 
immunocompromised individuals is extraordinarily high (Obritsch et al., 2005; 
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Pseudomonas aeruginosa Infections, 2006).  One study suggested a mortality rate of 67% 
in patients with multi-drug resistant infections (Obritsch et al., 2005).  The P. aeruginosa 
biconjugate vaccination has the potential to be a clinical precautionary necessity for 
individuals with Cystic Fibrosis, respiratory diseases, immune system disorders, cancer 
patients undergoing chemotherapy or bone marrow transplants, and burn victims. 
 Although competing, non-conjugate P. aeruginosa vaccinations exist, utilizing 
outer membrane proteins and flagella, they are still in clinical trials (Baumann et al., 
2007; Doring et al., 2007).  As for a technology-specific competitor, there are currently 
no other biconjugate vaccines on the market for P. aeruginosa.  The Swiss Serum and 
Vaccine Institute, along with Berna Biotech Ltd. of Switzerland are currently working on 
multivalent conjugate P. aeruginosa vaccines for children with Cystic Fibrosis (Cryz et 
al., 1997; Zuercher et al., 2006).  These technologies use LPS O-antigen linked to toxin 
A.  Djarid et al. at Tarbiat Medares University in Iran are also working on a biconjugate 
P. aeruginosa vaccine utilizing an alginate-tetanus conjugate (Kashef et al., 2006).  Szu 
et al. at Carolinas Medical Center in North Carolina will soon be entering a phase III 
clinical trial for a biconjugate vaccine of O157 O-antigen linked to P. aeruginosa 
exotoxin A (Ahmed et al., 2006).  These vaccinations use chemical cross-linking 
techniques to link the two molecules.  The 4 major problems associated with chemically 
cross-linking these vaccine components are; (1) it is expensive, (2) time-consuming, (3) 
requires growing up large quantities of harmful pathogens, and (4) cross-linking stability 
is unpredictable (Jones, 2005; Horzempa et al., 2008).   
 Despite this, multi-conjugate vaccines have reached the market.  Sanofi Pasteur, 
GSK, and Merck market conjugate vaccinations for tetanus, Haemophilus influenzae type 
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b (Hib), diphtheria, meningococcal, and pneumococcal (CDC, Vaccination Price List, 
2006).  This demonstrates that there is a market opportunity and well established 
corporations are already involved.  However, the vaccines currently on the market are 
produced by chemical cross-linking.  Dr. Castric’s technology eliminates the problems 
associated with chemical cross-linking.  Despite this, the integrity of adequate testability 
during clinical trials of the current vaccine technology presents itself as a potential 
challenge.  Although preliminary data of the current P. aeruginosa vaccine holds 
promise, competing conjugate technologies progressing through clinical trials have 
encountered several complications (Döring & Pier, 2008; Horzempa et al., 2008; 
Johansen & Gøtzsche, 2008).  First, increased sanitation and optimized antibiotic 
therapies may mask the true effectiveness of the vaccine (Döring & Pier, 2008).  Second, 
there is difficulty in acquiring a patient population large enough to produce statistically 
relevant data during clinical trials (Döring & Pier, 2008).  Third, basic research still needs 
to be done to further uncover the specifics of host immune responses to P. aeruginosa 
(Johansen & Gøtzsche, 2008).  However, with the continuous evolution of antibiotic 
resistant P. aeruginosa strains, vaccination is still a very appealing treatment option for 
the numerous patient populations at risk of infection by this opportunistic microbe.  
Because multiple groups are exploring P. aeruginosa conjugate vaccine development at 
the preliminary stage, undoubtedly, the breadth of basic immunological knowledge 
regarding P. aeruginosa infection will continue to expand.  Additionally, Dr. Castric’s 
vaccine technology harbors its significance in the potential to easily manufacture vaccine 
components to any number of pathogenic entities.   
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At this time Dr. Castric possesses three patents on the P. aeruginosa biconjugate 
vaccine.  The first is “Conjugate Vaccine Against Gram-Negative Bacterial Infections,” 
Patent #: US 6, 872, 398 B2, the second, “Compositions and Methods for Eliciting an 
Immune Response to Gram-Negative Bacterial Infections,” Patent #: US 7,132,101 B2 
and the third, “Compositions and Methods for Eliciting an Immune Response to Gram-
Negative Bacterial Infections,” Patent #: US 7,135,175 B2.  These patents cover the 
methods to produce and use the P. aeruginosa vaccine technology.  With these patents, 
the methods and technology can be licensed.   
 The P. aeruginosa conjugate vaccine offers benefits to the market place.  
Successful immunization against P. aeruginosa can have positive impacts on the health 
of patients and the finances of the health care provider.   For patients, the number of 
hospital visits should decline due to immunity against P. aeruginosa infection.  For 
example, if all 30,000 Cystic Fibrosis patients are immunized, this saves a potential 
30,000 initial visits to the doctor’s office or hospital as a result of a P. aeruginosa 
infection.   The cost and amount of antibiotic treatment should decline because of the 
need to use multiple antibiotics to treat multi-antibiotic resistant P. aeruginosa (Zavascki 
et al., 2006).  Also, this decline in antibiotics use will decrease the progress of P. 
aeruginosa becoming resistant to more antibiotics.   The length of hospital stays should 
decline due to a decrease of P. aeruginosa related nosocomial infections, resulting from a 
decrease in antibiotics resistance.  The average cost of hospitalizations due to multi-drug 
resistant infection was found to be about $54,000 per patient (Obritsch et al., 2005).   
Multidrug resistant P. aeruginosa, statistically, has been shown to prolong hospital stays 
up to six days, which accumulates an average $7,300 in extra care costs.  If these data are 
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applied to the 30,000 cystic fibrosis patients that inhabit the US, health care providers 
could save $219 million with this patient population alone (Obritsch et al., 2005).   
In 1995, it was estimated that nosocomial infections resulted in 88,000 deaths and 
cost over $4.5 billion (Weinstein, 1998). As stated earlier, P. aeruginosa infection 
accounts for roughly 30% of nosocomial infections in the United States.  Additionally, a 
study done in India estimated that about 25% of nosocomial infections were caused by P. 
aeruginosa (Agarwal et al., 2006).   If a quarter of nosocomial infections are cause by P. 
aeruginosa, the P. aeruginosa vaccine will save about $1 billion in expenses.  As of 
2006, the cost of community-acquired pneumonia, which can result from P. aeruginosa 
infection, was estimated to be about $9.7 billion annually (Harrison’s practice, 2006).  If 
a quarter of community-acquired infections are caused by P. aeruginosa, the P. 
aeruginosa vaccine could save about $2 billion dollars in expenses in this area.  For 
health care providers, the elimination of hospital-acquired and community-acquired P. 
aeruginosa infections saves roughly $3 billion in health care costs annually.   
 The conjugate vaccinations on the market range from $8.00-$120.00 per dose 
(CDC, Vaccination Price List, 2006).  For the projected revenues below I used an average 
value of $64 per dose.  If all Cystic Fibrosis patients were vaccinated, the projected gross 
revenue on this vaccination is $1,920,000.  The use of the vaccines as a preventive 
measure for those anticipating chemotherapy/immunosuppressant drugs, dependence on 
mechanical ventilation, and for burn victims, these earnings can be expected to increase.  
As of December 2006, there were 94,554 patients in the U.S. awaiting organ 
transplantation (OPTN, 2006).  If all of these patients are vaccinated the revenue would 
increase by $6,051,456.  The number of individuals suffering from COPD is estimated to 
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be about 12 million in the United States and 600 million worldwide (COPD Foundation, 
2009).  These patients are at a high risk of developing respirator-acquired P. aeruginosa 
infections.  In 1990, greater than 50% of COPD patients acquired a respiratory or 
pulmonary P. aeruginosa infection (Yu et al., 1990).  This number is expected to have 
increased due to drug-resistant Pseudomonas strains.  Immunization of these patients as a 
preventative measure would boost the projected revenue to $768,000,000 for the U.S. 
market and $38.4 billion when considering the global market.  The number of burn 
victims each year that require hospitalization is estimated to be about 20,000 (CDC, Mass 
Casualties Fact sheet; Burns, 2006).  Immunization of these patients is projected to be an 
additional $1,280,000 in revenue.   
If the breadth of this vaccination could be expanded to cover other gram-negative 
pathogens, the return would be even greater.  For example, the CDC estimates that there 
is over 73,000 E. coli O157 cases reported annually in the United States (CDC, 
Escherichia coli O157:H7, 2008).  If vaccine production can be extended to include this 
pathogen, a vaccination against E. coli O157 should bring in an additional projected 
$4,672,000 per year.   
Additionally, the CDC also estimates that 90,000 people a year acquire 
nosocomial infections (Infection Control Related Sentinel Events, 2003).  Making the 
assumptions that 30,000 of these infections are acquired by Cystic Fibrosis patients 
(90,000 – 30, 000CF = 60,000) and that the vaccine can be extended to other gram-
negative bacterial pathogens, this adds an additional projected revenue of $3,840,000 per 
year.  The sum of these projections could provide a total projected revenue of 
$785,763,456.   These estimated returns are based on U. S. incidence alone, not 
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worldwide.  With global incidence of infection caused by gram-negative pathogens the 
total revenue is over $38.5 billion.      
 Although it has been shown that key aspects of the technology are applicable to 
other gram-negative bacteria, the ability of expanding vaccine production to other 
pathological conditions exists as a challenge of future application.  It has yet to be shown 
to be applicable to gram-positive bacteria, cancers, viruses, or any other non-bacterial 
protein.  Also, Dr. Castric’s vaccine technology may be used to produce biconjugate 
animal vaccines.  For example, E. coli O157 and Salmonella are constant concerns for 
cattle and poultry farmers, as well as the consumer.  Ability to produce animal-
vaccinations also expands this technologies potential market.   
 Overall, the biconjugate P. aeruginosa vaccination appears to be a modest 
marketing opportunity in the U.S.  However, the current global vaccine market is 
estimated at about $9 billion.  At this time, the earnings in the vaccine market are just as 
successful as the market for conventional drugs (Marx, 2005).  In the U.S., it is estimated 
that 30,000 patients suffer from Cystic Fibrosis, and globally, 600 million patients are 
estimated to suffer from COPD.  If only 10% of this combined patient population 
receives the P. aeruginosa vaccination, Dr. Castric’s technology could still potentially 
capture over $3.84 billion of the world vaccine market. For a company licensing this 
technology, this projection is sufficient to support the cost of clinical trials.  Globally, the 
marketing opportunity of this vaccine technology has the potential to be remarkably 
large.   
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H.  Significance of Current Research----Thesis Goals  
 
The main objective of my thesis research was to study substrate specificity in 
protein glycosylation reactions.  Specifically, the minimal glycosylation requirements 
will be assessed using a structurally different pilin, a pilin fusion protein, and a bacterial 
alkaline phosphatase protein in P. aeruginosa.  The current work is an extension of 
Horzempa et al.’s study on glycosylation substrate specificity of pilin in P. aeruginosa 
strain 1244 (Horzempa et al., 2006a).  Overall, Horzempa et al. showed that the minimal 
requirement for glycosylation is a C-terminal serine residue and an electropositive 
surface charge (Horzempa et al., 2006a).  In this study, Horzempa et al. were able to 
glycosylate the normally non-glycosylated PA103 pilin in P. aeruginosa by extending a 
C-terminal serine residue away from the electronegative surface with a “tail” of alanines 
(Horzempa et al., 2006a).  The current research utilized this strategy to assess the 
compatibility of several distinct mutant proteins in the P. aeruginosa glycosylation 
reaction.   
In 2002, DiGiandomenico et al. demonstrated the flexibility of the pilin 
glycosylation reaction by showing the O-antigen repeating unit of E. coli O157 could be 
used to glycosylated PA1244 pilin in vivo, and also that PA1244 pilAO could glycosylate 
pilin with native repeating units in other P. aeruginosa serotypes (DiGiandomenico et al., 
2002).  In 2006, Horzempa et al. was able to show that this flexibility occurs as a result 
of the PilO protein’s recognition of the reducing end glycan residue, which possess a 
similar structure across gram negative O-antigen subunits (Horzempa et al., 2006b).   
Collectively, these findings suggest applications to in vivo generation of vaccine 
components.  The LPS of gram negative bacteria is the predominant immunogenic 
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surface structure (Pier, 2007).  The saccharide residues that make up the LPS are able to 
elicit a T-independent immune response, but no immunogenic memory is established 
(Mond et al., 1995).  However, a T-dependent immune response is achieved when LPS 
saccharides are covalently conjugated to a protein (Avery & Goebel, 1931; Mond et al., 
1995; Lesinski & Westerink, 2001; Wourimaa et al., 2001).  This memory eliciting 
response generated towards both components, the saccharide and protein, is the working 
principle behind glycoconjugate vaccine production.  Glycoconjugate vaccinations are 
currently marketed, however, their production is expensive and time consuming 
compared to the proposed technology (Jones, 2005; Horzempa et al., 2008).  Dr. Castric’s 
glycoconjugate vaccine technology utilizes P. aeruginosa to covalently link a single O-
antigen repeating unit to a pilin molecule via the native glycosylation mechanism, 
thereby producing multi-valent vaccine components in vivo.  Pilin is a prime protein for 
glycoconjugation because it has previously been shown to elicit a memory response 
(Ohama et al., 2006), which suggests the ability to confer this memory on the covalently 
linked saccharide.   
In 2008, Horzempa et al. confirmed this notion, by showing that pure 
glycosylated PA1244 pilin provided protection against a PA1244 LPS-producing mutant 
that lacked pilus formation in mouse pneumonia and burn models (Horzempa et al., 
2008).  This study suggests mechanisms by which the vaccine eliminates bacterial 
infection.  A memory response could result in the immune system targeting pili and the 
O-antigen.  Targeting pili would eliminate adhesion and twitching motility, eliminating 
colonization establishment and expansion.  Targeting the O-antigen would target the 
bacteria for clearance by opsonic phagocytosis.   
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  Fundamentally, the current study may be able to provide further information on 
pilin glycosylation specificity. Since PA103 pilin was able to be engineered for 
glycosylation, it is hypothesized that all of the proposed proteins in this study can 
similarly be engineered for glycosylation.  If any number of these mutagenized proteins 
are able to be glycosylated, these findings would hold practical applications for the 
research and design of multi-valent vaccine production.  Further identification of 
substrate specificity of the glycosylation reaction in P. aeruginosa could potentially allow 
a variety of bacterial or pathogenic protein epitopes to be covalently conjugated to highly 
compatible immunogenic LPS O-antigen repeating units, producing memory eliciting 
antigenic entities to multiple pathogens by a readily inducible microbial physiological 
mechanism.  Successful manipulation of this glycosylation system could expand the 
breadth of pathogenic targets while maintaining cheap and easily manufactured multi-
valent vaccine components.  The current research examines the ability to glycosylate 
proteins other than PA1244 pilin, in P. aeruginosa.   
 
 
Specific Aims: 
1.  Can a structurally different, Group III, pilin be engineered to accept the O-antigen 
repeating unit of lipopolysaccharide? 
2.  Can a protein fused to pilin be engineered to accept the O-antigen repeating unit of 
lipopolysaccharide? 
3.  Can a non-pilin protein be engineered to accept the O-antigen repeating unit of 
lipopolysaccharide? 
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II.  MATERIALS AND METHODS 
 
 
 
A.  Media and Bacterial Strains  
All bacterial strains and plasmids used in the study can be found in Table 1.  
Strains were aerobically grown in Luria Bertani (LB) (0.5% yeast extract, 1% bacto-
tryptone, 1% sodium chloride) broth cultures, on LB agar plates, or on CAYE (0.75% 
casamino acids, 0.15% yeast extract, 2% agar [Silipigni-Fusco, 1987]) agar pans (68 cm 
X 28 cm X 3 cm).  All strains aerobically grown in LB broth cultures were done so at 
37oC and 250 rpm.  All strains grown on LB agar plates or CAYE agar pans were done so 
at 37oC.  Antibiotic concentrations for E. coli were kanamycin at 35-50 µl/ml, ampicillin 
at 50-100 µg/ml, and tetracycline at 15 µg/ml.  Antibiotic concentrations for P. 
aeruginosa were carbenicillin at 250 µg/ml and tetracycline at 50-100 µg/ml.  IPTG 
(Isopropyl-β-D-Thiogalactopyranoside) was added to the media of all strains to induce 
expression of recombinant genes under control of the tac promoter in pMMB66EH, the 
lacI promoter in pRMCD28, and the trc promoter in pHK734 at a concentration of 0.5 
mM for E. coli and 5mM for P. aeruginosa.   
 
Table 1.  Bacterial Strains and Plasmids  
Bacterial Strain Description  Reference  
E. coli  Top10®  F- mcrA ∆(mrr-hsdRMS-mcrBC) 
Φ80lacZ∆M15 ∆lacΧ74 recA1 araD139 
∆(araleu) 
7697 galU galK rpsL (StrR) endA1 nupG 
Invitrogen 
E.coli  XL-Gold®  endA1 supE44 thi-1 recA1 gryA96 relA1 
lacHte 
Stratagene  
E.coli HB101  supE44 hsdS20 recA13 ara-14 proA2 
lacY1 galK2 rpsL20 xyl-5 mtl-1 
Bolivar & 
Backman, 1979  
PA1244 Wild type, Serotype O7 Ramphal et al., 
1984  
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PA1244-N3 Interruption of sigma factor rpoN with Tc 
cassette, TcR 
Ramphal et al., 
1991  
PA103 Wild type, Serotype O11 Liu, 1973  
PA103 wzyPaO11::aacC1 PA103 wzyPaO11::aacC1, Interruption of 
wzy gene with a Gm cassette (aacC1) GmR 
Dean et al., 1999 
PA683 Wild type, Non-Typable Serotype Seyboldt Thesis, 
1996 
Plasmid  Description  Reference  
pUCP26 4,977bp broad host-range cloning vector, 
pUC18-derived, TcR 
West et al., 1994 
pUCP26pilO pUCP26 with pilO under continuos 
expression from a tac promoter  
Horzempa et al., 
2006a 
pMMB66EH 8, 807bp broad host-range expression 
vector, IPTG inducible tac promoter, 
AmpR/CbR 
Fürste et al., 1986 
p683pilA pMMB66EH with PA683 pilA This study 
p683pilA-tfpY pMMB66EH with PA683 pilA-tfpY This study 
p683aas pMMB66EH with mutated PA683 pilA 
that had an ala-ala-ser-stop extension 
added to the C-terminal arginine residue 
This study 
p683pep pMMB66EH with mutated PA683 pilA 
that had the C-terminal 15 amino acids of 
PA1244 pilA, with the C-proximal 
cysteine changed to an alanine and 
addition of a stop codon 
(TAWKPNYAPANAPKS-stop) to the C-
terminal arginine residue  
This study 
pRMCD28 PhoA fusion vector, PhoA starts at the 27th 
amino acid encoding codon, AmpR 
Daniels et al., 
1998 
pPilAPhoA pRMCD28 with PA1244 pilA-E. coli phoA 
fusion, KAYRYRR linker, phoA is 
missing the N-terminal amino acids 1-27 
This study 
pPilAP pMMB66EH with PA1244 pilA-E. coli 
phoA fusion 
This study 
pPilAPaas pMMB66EH with mutated PA1244 pilA-
E. coli phoA fusion that had an ala-ala-ser-
stop extension added to the C-terminal 
lysine residue 
This study 
pHK734 E. coli phoA gene under the trc promoter 
of pTrc99a, AmpR 
Gift from Jon 
Beckwith 
pECAP pMMB66EH with E. coli phoA from 
pHK734 
This study 
pECAPaas pMMB66EH with mutated E. coli phoA 
that had an ala-ala-ser-stop extension 
added to the C-terminal lysine residue 
This study 
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B.  Homology Modeling  
Homology models were generated using the PHYRE software online 
(http://www.sbg.bio.ic.ac.uk/phyre/index.cgi).  Peptide sequences of PA1244 pilin, 
PA683 pilin, and bacterial alkaline phosphate were submitted to the PHYRE program.  
The tertiary homology structural output was analyzed using DS Viewer Pro 6.0 for 
surface exposed C-terminal residues and surface charge.   
 
C.  Plasmid Construction  
All primers used in this study can be found in Table 2.  All constructs were 
confirmed with one or a combination of restriction enzyme digestion, PCR screen, or 
sequencing.   
Table 2.  Primer List  
Primer Name  Sequence (5’-3’) Use  
Promoter into pilA 
(683PilA-F) 
GCC CTT TCA CTA GCT TGC TC Amplify PA683 pilA 
from genome 
Primer G 
(683PilA-R1) 
CAG ATG ATT GCC AGC AAT Amplify PA683 pilA 
from genome  
XmaI-PilA-F CAT TAG CCC GGG GCC CTT 
TCA CTA GCT TGC TC 
PCR amplify PA683 
pilA(-AAS, -Tail) 
adding XmaI site 
HindIII-PilA-R1 CAT TAG AAG CTT CAG ATG 
ATT GCC AGC AAT 
PCR amplify PA683 
pilA adding HindIII site 
HindIII-TfpY-R1 CAT TAG AAG CTT TAC GAA 
TGA GCT GCT CTA CC  
PCR amplify PA683 
pilA-tfpY adding 
HindIII site 
HindIII-683PilA-AAS-R CAT TAG AAG CTT TTA GCT 
AGC AGC GCG GCA TTC GCT 
CGG AGC 
PCR amplify PA683 
pilA  adding C-term -
AAS codons and 
HindIII site 
HindIII-683PilA-Tail-R CAT TAG AAG CTT TTA GGA 
TTT CGG GGC ATT AGC CGG 
AGC GTA GTT GGG CTT CCA 
AGC TGT GCG GCA TTC GCT 
CGG AGC 
PCR amplify PA683 
pilA adding C-term 
altered PA1244 pilA 
peptide tail and HindIII 
site 
683PilA-Cterm TCG GAA TCC AAT GCG GTT TC For sequencing, 100bp 
upstream of 683 pilA 
C-term 
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EcorI-PilA-Promoter GAA TTC AGG TTG GCA TGC 
AAC CTG CT 
PCR amplify PA1244 
pilA from genome 
adding EcoRI site 
PilA-HindlII CAT TAG AAG CTT TGG ATT 
TCG GGC AAT TAG CCG GAG CG 
PCR amplify PA1244 
pilA from genome 
adding HindIII site  
PilA-Cterm GCT GTA ATC ACT GTT TCG CG For sequencing, 100bp 
upstream from pilA C-
term 
EcoRI-1244PilA-F CAT TAG GAA TTC AGG TTG 
GCA TGC AAC CTG CT 
PCR amplify PA1244 
pilA-EC phoA fusion 
adding EcoRI site 
BamHI-ECAP-R CAT TAG GGA TCC TTA TTT 
CAG CCC CAG AGC GGC 
PCR amplify PA1244 
pilA-EC phoA fusion 
adding BamHI site 
XmaI-1244PilA-F CAT TAG CCC GGG AGG TTG 
GCA TGC AAC CTG CT 
PCR amplify PA1244 
pilA-EC phoA fusion 
adding XmaI site 
SalI-ECAP-AAS-R CAT TAG GTC GAC TTA GCT 
AGC AGC TTT CAG CCC CAG 
AGC GGC 
PCR amplify PA1244 
pilA-EC phoA fusion 
adding SalI site and –
AAS to C-term 
Ecoli-AAS-F GCT CTG GGG CTG AAA GCT 
GCT AGC TAA AAC CGC GCC 
CGG 
Mutate EC PhoA C-
term by adding -AAS 
Ecoli-AAS-R CCG GGC GCG GTT TTA GCT 
AGC AGC TTTCAG CCC CAG 
AGC  
Mutate EC PhoA C-
term by adding -AAS 
PhoACterm-Ecoli TCA CAA GAA CAT ACC GGC AG For sequencing, 100bp 
upstream of EC phoA 
C-term 
 
 
1.  Construction of p683pilA 
To make the p683pilA construct, PA683 pilA was amplified from PA683 genomic 
DNA using PCR and primers, 683PilA-F and 683PilA-R1.  Thermocycler conditions for 
this PCR reaction consisted of a 105oC lid temperature, initial incubation at 94oC for 7 
minutes, followed by 30 cycles of 94oC denature for 1 minute, 50 oC annealing for 1 
minute, and 72oC extension for 2 minutes.  The final extension was 72oC for 7 minutes 
and stored at either 4oC or 21oC.  This amplified PA683 pilA sequence was then run on a 
0.8% agarose gel and gel extracted using the Qiagen QIAquick® Gel Extraction Kit 250 
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(catalog# 28706, Valencia, CA).  This gel extracted PA683 pilA fragment was then 
amplified using primers that contained XmaI and HindIII sites, XmaI-PilA-F and HindIII-
PilA-R1.  Thermocycler conditions for this PCR reaction were the same as the first 
primer set.  This amplified version of the PA683 pilA sequence was then cloned into the 
pCR®2.1-TOPO® vector using Invitrogen’s TOPO TA Cloning® Kit. The PA683 pilA 
sequence was cut out of the pCR®2.1-TOPO® vector using XmaI/HindIII and ligated into 
pMMB66EH that was cut with the same restriction enzymes to form the p683pilA 
construct.  PilA expression is under the control of the IPTG-inducible plasmid promoter. 
 
2.  Construction of p683pilA-tfpY 
To make the p683pilA-tfpY construct, PA683 pilA-tfpY was amplified from 
PA683 genomic DNA using PCR and primers designed to contain XmaI and HindIII 
sites, XmaI-PilA-F and HindIII-TfpY-R1.  Thermocycler conditions for this PCR 
reaction consisted of a 105oC lid temperature, initial incubation at 94oC for 7 minutes, 
followed by 30 cycles of 94oC denature for 1 minute, 50 oC annealing for 1 minute, and 
72oC extension for 2 minutes.  The final extension was 72oC for 7 minutes and stored at 
either 4oC or 21oC.  This amplified version of the PA683 pilA-tfpY sequence was then 
cloned into the pCR®2.1-TOPO® vector using Invitrogen’s TOPO TA Cloning® Kit. The 
PA683 pilA-tfpY sequence was cut out of the pCR®2.1-TOPO® vector using 
XmaI/HindIII and ligated into pMMB66EH that was cut with the same restriction 
enzymes to form the p683pilA-tfpY construct.  PilA-TfpY expression is under the control 
of the IPTG-inducible plasmid promoter. 
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3.  Construction of p683aas 
To make the p683aas construct, primers designed to flank the ends of the 683 pilA 
sequence, contain codons for a C-terminal –AAS extension, and contain XmaI and 
HindIII restriction sites were used to PCR out mutant 683 pilA-AAS from the p683pilA 
vector.  The primers are named XmaI-PilA-F and HindIII-683PilA-AAS-R.  
Thermocycler conditions for this PCR reaction consisted of a 105oC lid temperature, 
initial incubation at 94oC for 7 minutes, followed by 30 cycles of 94oC denature for 1 
minute, 53.5oC annealing for 1 minute, and 72oC extension for 2 minutes.  The final 
extension was 72oC for 7 minutes and stored at either 4oC or 21oC.  This amplified 
product was then cloned into the pCR®2.1-TOPO® vector using Invitrogen’s TOPO TA 
Cloning® Kit. The PA683 pilA-AAS sequence was cut out of the pCR®2.1-TOPO® vector 
using XmaI/HindIII and ligated into pMMB66EH that was cut with the same restriction 
enzymes to form the p683aas construct.  Mutant PilA-AAS expression is under the 
control of the IPTG-inducible plasmid promoter. 
 
4.  Construction of p683pep 
To make the p683pep construct, primers designed to flank the end of the 683 pilA 
sequence, contain codons for a C-terminal – peptide tail mutation                                     
(-TAWKPNYAPANAPKS) consisting of the C-terminal 15 amino acids of PA1244 PilA 
(with the C-proximal cysteine residue changed to alanine), and contain XmaI and HindIII 
restriction sites were used to PCR amplify mutant 683 pilA with the peptide tail from the 
p683pilA vector.  The primers are named XmaI-PilA-F and HindIII-683PilA-Tail-R.  
Thermocycler conditions for this PCR reaction consisted of a 105oC lid temperature, 
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initial incubation at 94oC for 7 minutes, followed by 30 cycles of 94oC denature for 1 
minute, 53.5oC annealing for 1 minute, and 72oC extension for 2 minutes.  The final 
extension was 72oC for 7 minutes and stored at either 4oC or 21oC.  This amplified 
product was then cloned into the pCR®2.1-TOPO® vector using Invitrogen’s TOPO TA 
Cloning® Kit. The PA683 pilA with the peptide tail sequence was cut out of the pCR®2.1-
TOPO® vector using EcoRI/HindIII and ligated into pMMB66EH that was cut with the 
same restriction enzymes to form the p683pep construct.  Mutant PilA (with peptide tail) 
expression is under the control of the IPTG-inducible plasmid promoter. 
 
5.  Construction of pPilAPhoA: 
To make the pPilAPhoA fusion construct, PA1244 pilA was amplified from the 
PA1244 genome using PCR and primers, EcoRI-PilA-Promoter to add a 5’-EcoRI site 
and PilA-HindIII to add a 3’-HindIII site.  Thermocycler conditions for this PCR reaction 
consisted of a 105oC lid temperature, initial incubation at 94oC for 7 minutes, followed by 
30 cycles of 94oC denature for 1 minute, 45-65oC annealing gradient for 1 minute, and 
72oC extension for 1 minute.  The final extension was 72oC for 7 minutes and stores at 
either 4oC or 21oC.  PA1244 pilA was then cloned into the pCR®2.1-TOPO® vector using 
Invitrogen’s TOPO TA Cloning® Kit.  PA1244 pilA was cut out of the pCR®2.1-TOPO® 
vector using XbaI/HindIII and then ligated, in frame with phoA, into pRMCD28 vector 
cut with the same restriction enzymes to form the pPilAPhoA fusion construct.  Fusion 
expression is under the control of the IPTG-inducible plasmid promoter. 
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6.  Construction of pPilAP 
 To make the pPilAP construct, the fusion sequence was amplified from 
pPilAPhoA using primers designed to flank the ends of the fusion sequence and contain 
EcoRI and BamHI restriction sites.  The primers are named EcoRI-1244PilA-F and 
BamHI-ECAP-R.  Thermocycler conditions for this PCR reaction consisted of a 105oC 
lid temperature, initial incubation at 94oC for 7 minutes, followed by 30 cycles of 94oC 
denature for 1 minute, 53.5oC annealing for 1 minute, and 72oC extension for 2 minutes 
and 30 seconds.  The final extension was 72oC for 7 minutes and stored at either 4oC or 
21oC.  This amplified fusion sequence was then cloned into the pCR®2.1-TOPO® vector 
using Invitrogen’s TOPO TA Cloning® Kit. The fusion sequence was cut out of the 
pCR®2.1-TOPO® vector using EcoRI/BamHI and ligated into pMMB66EH that was cut 
with the same restriction enzymes to form the pPilAP construct.  Because the phoA 
sequence contains several EcoRI sites, partial digestion with this enzyme was performed 
for 30 seconds at 37oC.  Fusion expression is under the control of the IPTG-inducible 
plasmid promoter. 
 
7.  Construction of pPilAPaas 
To make the pPilAPaas construct, primers designed to flank the end of the fusion 
sequence and contain the C-terminal –AAS mutation and XmaI and SalI restriction sites 
were used to PCR out the fusion from the pPilAPhoA vector.  The primers are named 
XmaI-1244PilA-F and SalI-ECAP-AAS-R.  Thermocycler conditions for this PCR 
reaction consisted of a 105oC lid temperature, initial incubation at 94oC for 7 minutes, 
followed by 30 cycles of 94oC denature for 1 minute, 53.5oC annealing for 1 minute, and 
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72oC extension for 3 minutes and 30 seconds.  The final extension was 72oC for 7 
minutes and stored at either 4oC or 21oC.  This amplified version of a mutated fusion 
sequence was then cloned into the pCR®2.1-TOPO® vector using Invitrogen’s TOPO TA 
Cloning® Kit. The mutated fusion sequence was cut out of the pCR®2.1-TOPO® vector 
using XmaI/SalI and ligated into pMMB66EH that was cut with the same restriction 
enzymes to form the pPilAPaas construct.  Mutant fusion-AAS expression is under the 
control of the IPTG-inducible plasmid promoter. 
 
8.  Construction of pECAP 
To make the pMMB66EH+E. coli (EC) alkaline phosphatase (AP) construct, 
pECAP, the EC phoA sequence was cut out of pHK734 using EcoRI/BamHI.  pHK734 
was a gift from Hiroshi Kadokura and Jon Beckwith (Harvard Medical School 
Department of Microbiology and Molecular Genetics).  Because the phoA sequence 
contains several EcoRI sites, partial digestion with this enzyme was performed for 30 
seconds at 37oC.  This cut EC phoA sequence was then ligated into pMMB66EH cut with 
the same restriction enzymes.  PhoA expression is under the control of the IPTG-
inducible plasmid promoter. 
 
9.  Construction of pECAPaas 
Site-directed mutagenesis was used to add an alanine-alanine-serine (-AAS) 
extension to the C-terminal lysine residue of EC PhoA of pECAP to form the pECAPaas 
construct.    The mutagenic primers are named Ecoli-AAS-F and Ecoli-AAS-R.  This site 
directed mutagenesis was performed using Stratagene’s QuikChange® II XL Site-
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Directed Mutagenesis kit, following the instruction manual protocol.  However, the PCR 
reaction was divided into two half-reactions.  One half-reaction contained the forward 
primer and the second half-reaction contained the complimentary primer.  These 
reactions were run for three cycles of the kit thermocycler amplification conditions.  
After three cycles, the reactions were stopped, the two half-reactions were combined into 
one reaction tube, and then the mutagenic PCR conditions were started again from the 
beginning and allowed to run to completion.   Since the construct was so large, this 
technique allowed half-templates to be produced, ensuring proper annealing and 
replication of the mutagenized product.  Mutant PhoA-AAS expression is under the 
control of the IPTG-inducible plasmid promoter. 
 
D.  Transformation of Strains  
1.  Chemical:   
Two chemical transformation protocols were used in this study.  Transformation 
of pCR2.1-TOPO vector (with or without insert) was carried out according to Invitrogen 
TOPO TA Cloning® Kit’s OneShot® Chemical Transformation protocol.  This 
transformation protocol allowed transformation of plasmid into kit provided Top10® E. 
coli cells.    
All other plasmid constructs were chemically transformed, using the general 
laboratory protocol, into E. coli HB101 cells.  HB101 cells were made competent by 
aerobically growing them to early log phase and then treating with half the original 
volume of an ice-cold, filter sterilized solution of 50 mM CaCl2, 10 mM Tris-HCl pH8.0, 
incubating on ice for 15 minutes, then spinning to pellet the cells.  The cells are then 
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treated with 1/15 the original volume of an ice-cold, filter sterilized solution of 50 mM 
CaCl2, 10 mM Tris-HCl pH8.0, 10% glycerol and stored in this suspension at -80oC.   
Forty-five microliters of competent HB101 cells were aliquoted into a sterile, 
thin-walled polypropylene culture tube.  To these cells, 2.5 µl of transforming DNA was 
added and incubate on ice for 30 minutes.  This suspension was heat shocked at 42oC for 
30 seconds, then quickly put on ice for 2 minutes.   Two hundred fifty microliters 
NZYE+ (1% NZ Amine/casein hydrolysate, 0.5% Yeast Extract, 0.5% NaCl, pH7.5, 12.5 
mM MgSO4, 12.5 mM MgCl2, 0.4% glucose) broth was added to the cells and incubated 
for 1 hour at 37oC, 250 rpm.  The desired amount of transformation reaction was plated 
onto selective media and incubated under optimal aerobic conditions.   
 
2.  Electroporation: 
 Strains of P. aeruginosa were aerobically grown at 37oC, 250 rpm in LB broth to 
early log phase.  Subsequently, 4 ml of cell culture was distributed into four 1.5 ml 
microfuge tubes.  These cells were pelleted and washed with 300 mM sucrose (room 
temperature).  Cells were resuspended in 100 µl of 300 mM sucrose and transferred into 
one 1.5 ml microfuge tube.  To this cell suspension, approximately 5-7µl of high copy 
(10-30 µl low copy) transforming DNA was added.  This suspension was mixed briefly 
by gently pipetting up and down and then transferred to an electroporation cuvette.  
Electroporation, as specified by Choi et al., was carried out with the BIO-RAD Gene 
PulserTM set to 25 µF, 200 Ω, 2.5 kV (Choi et al., 2006).  One pulse generally took 
between 3-4 seconds.  After this pulse, 1 ml of LB broth was added to the cuvette and 
gently mixed by briefly pipetting up and down.  The transformation reaction was then 
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transferred to a sterile, thin-walled polypropelyne culture tube and incubated for 1 hour at 
37oC, 250 rpm (Choi et al., 2006).  After incubation, varying volumes (usually 20 µl and 
50 µl) of this transformation reaction were plated onto selective media and incubated 
overnight at 37oC.   
 
E.  Alkaline Phosphatase Periplasmic Activity Assay  
  This assay protocol was adapted from Daniels et al. 1998.  All strains were 
cultured overnight under aerobic conditions with respective antibiotic for selection.  
Subcultures were diluted to 1:20 with fresh LB, induced at 5 mM IPTG, and incubated at 
37oC, 250 rpm for 1.5 hours.  The cultures were normalized to an optical density of 0.5-
0.6 at A600 using a Spectronic® 20 GenesysTM.  The cells were pelleted and washed with 
cold 10 mM Tris-HCl pH8.0, 10 mM MgSO4.  The cells were resuspended in 1 ml cold 
1M Tris-HCl pH8.0, 1 mM iodoacetamide.  Two hundred microliters of cell suspension 
was added to 800 µl 1M Tris-HCl ph8.0, 0.1 mM ZnCl2, 1 mM iodoacetamide.  To this 
suspension,  
50 µl 0.1% SDS and 50 µl chloroform was added to permeabilize the cells (creating 
spheroplasts).  Two hundred seventy-five microliters of this cell suspension was added to 
the well of a 96-well plate in triplicate.  The reaction was started with the addition of  
25 µl 0.4% p-nitrophenyl phosphate, covered with foil, and incubated at 37oC for 30 
minutes.  The reaction was stopped with the addition of 20 µl 0.5 M 
ethylenediaminetetraacetic acid (EDTA) pH8.0.   The optical density was taken at an 
absorbance of 415 nm for color change and 595 nm for cell debris using a BIO-RAD 
Model 3550 Microplate Reader (courtesy of Dr. Kyle Selcer).  Microsoft Excel was used 
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to calculate periplasmic alkaline phosphatase activity using absorbencies taken at 415 
nm, 595 nm, and 600 nm.  
 
Units Activity = [OD415 – (1.75 X OD595)]1000 
Time (min) X OD600 X vol. cells (ml) 
 
 
 
F.  Extraction of Soluble and Insoluble Cell Fractions  
Pseudomonas aeruginosa strains were grown aerobically overnight at 37oC on LB 
plates.  Plate grown P. aeruginosa cells are known to increase piliation (Silipigni-Fusco, 
1987).  The entire lawn of cells was resuspended in 5 ml of lysis buffer (10 mM K2HPO4, 
30 mM NaCl, 0.25% Tween-20, 10 mM β–mercaptoethanol, 10 mM EDTA, 10 mM 
EGTA) and stored at -80oC for 30 minutes.  To the thawed cell suspension, 1ml of 
lysozyme (100 µg/1ml lysis buffer) was added, briefly vortexed, and incubated on ice for 
30 minutes.  Sonication was then performed on the cell suspension 3 times at 15 second 
intervals on ice (with 1 minute breaks on ice between sonication intervals).  The 
suspension was then centrifuged at 9,000 rpm with a DuPont Sorvall® SS-34 rotor 
(Thermo Fischer Scientific, Waltham, MA) for 15 minutes at 4oC.  The supernatant, 
containing the soluble (S) cytosolic/periplasmic and insoluble (IS) membrane cell 
fractions, was immediately transferred to a new centrifuge tube and kept on ice.  The 
supernatant was then centrifuged at 32,000 rpm with a Beckman SW60Ti rotor (Beckman 
Coulter, Inc., Fullerton, CA) for 1 hour at 4oC.  The supernatant is the soluble fraction 
(SF) and the pellet is the insoluble fraction (ISF).  The ISF pellet was resuspended in 200 
µl lysis buffer.  Both fractions were stored at -21oC until further preparation or analysis.  
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Protein concentration was determined using the Pierce BCATM Protein Assay Kit.  
Further preparation of these samples for SDS-PAGE and Western analysis is provided 
blow under “Western Blot: Sample Preparation.”   
 
G.  Extraction of Periplasmic Fraction  
The current protocol was obtained from Jayashree Rao’s thesis (Rao, 1995), 
which is an adaptation of the Poole and Hancock periplasmic extraction protocol (Poole 
& Hancock, 1984).  Pseudomonas aeruginosa strains were grown aerobically overnight 
at 37oC on LB plates.  Plate grown P. aeruginosa cells are known to increase piliation 
(Silipigni-Fusco, 1987).  The entire lawn of cells was resuspended in 20 ml 0.01 M 
Tris/HCl pH 7.5.  This cell suspension was split into two centrifuge tubes, 10 ml per tube.  
The samples were then centrifuged at 7,500 rpm with a Sorvall® SS-34 rotor for 10 
minutes at 4oC.  The pelleted cells were resuspended in 10 ml of 0.01 MTris/HCl pH 7.5.  
To this suspension, 200 µl of 0.1M EDTA and 1 ml lysozyme (25 mg/ml in 0.01 M 
Tris/HCl pH 7.5) was added and incubated on ice for 25 minutes.  The sample was then 
centrifuged at 7,500 rpm with a Sorvall® SS-34 rotor for 10 minutes at 4oC.  The 
supernatant (periplasmic fraction) was transferred to a 14 ml Falcon tube and stored at -
21oC until further preparation or analysis.  Further preparation of these samples for SDS-
PAGE and Western analysis is provided below under “Western Blot: Sample 
Preparation.”   
 
 
 
72 
H.  Isolation of Pili 
Four IPTG-induced, LB agar plate grown cultures (entire lawn) were resuspended 
in 10 ml fresh LB broth (in centrifuge tubes) after 14-18 hours at 37oC.  The cells were 
vortexed for 2-3 minutes to shear the pili from the cells.  As an additional shearing step, 
the cell suspension was passed through an 18-gauge needle 4 times.  The suspension was 
then centrifuged at 10,000 rpm for 30 minutes at 4oC with a Sorvall® SS-34 rotor.  The 
supernatant (pili) was transferred to a new centrifuge tube and 7.8 ml 5X polyethylene 
glycol (PEG)/NaCl (15% PEG, 2.5 M NaCl) was added to each sample (for 32.05 g pili 
suspension).  The samples were mixed thoroughly by vortexing, incubated on ice for 2 
hours, and then centrifuged again at 10,000 rpm for 30 minutes at 4oC with a Sorvall® SS-
34 rotor.   The pellet (pili) was resuspended in 1ml sterile deionized water and transferred 
to a 1.5 ml microfuge tube.  200 µl 5X PEG/NaCl was added, mixed thoroughly by 
vortexing, and incubated on ice for 30-45 minutes.  The sample was then microfuged at 
14, 500 rpm (or at max) in a microcentrifuge for 10 minutes.  The pellet (pili) was 
resuspended in 1ml sterile deionized water and subjected to dialysis to remove buffers 
and salts.  The sample was transferred to Fisherbrand® regenerated cellulose dialysis 
tubing (catalog# 21-152-7, Fisher Scientific, Suwanee, GA) and stirred at 4oC overnight 
in 6 liters of deionized water with 1.5 g sodium azide.  The dialyzed sample was then 
lyophilized in a LABCONCO Freeze Dry System/Freezone® 4.5 (Kansas City, MO) 
overnight.  The lyophilized sample was resuspended in 500-650 µl sterile deionized water 
and stored at -20oC as a native stock.  For SDS-PAGE analysis, the native stock was 
diluted in a 1:1 ratio with 2X loading buffer and prepared as stated below in the section 
entitled “Western Blot: Sample Preparation.”   
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I.  Western Blot  
1.  Sample Preparation: 
For whole cell extracts, all broth and plate grown cells were normalized to an 
optical density reading of 0.5-0.6 at an absorbance of 650 nm.  One and one half 
mililiters of cells was centrifuged at 14, 500 rpm (or at max) for one minute in a 
microcentrifuge to pellet the cells.  The cell pellet was then respsuspended in 250 µl of 
1X Loading Buffer (62.5 mM Tris/HCl pH6.8, 2% SDS, 10% glycerol, 2.5% β-
mercaptoethanol, 0.0025% Bromophenol Blue) and incubated on a heat block at 95oC for 
10 minutes.  Samples were stored at 4oC.   
 Cell fractions and pili preparations were subjected to dialysis and lyophilization to 
remove buffer salts/contaminants and further concentrate the sample.  All cell fractions 
were normalized for protein concentration by using the Pierce BCATM Protein Assay Kit 
(prod# 23225) and standard curve analysis.   Cell fraction/pilin samples and 2X Loading 
Buffer (125 mM Tris/HCl pH6.8, 4% SDS, 20% glycerol, 5% β-mercaptoethanol, 
0.005% Bromophenol Blue) were added in a 1:1 ratio.  The samples were then incubated 
on a heat block at 95oC for 10 minutes.  Samples were stored at 4oC.   
 
2.  SDS-PAGE Gel Preparation: 
 Polyacrylamide gels were prepared to concentrations between 10% T and 16%  T 
for protein separation and 5% T for the top stacking layer in 1.0 mm Invitrogen cassettes.  
Bio-Rad Prestained SDS-PAGE Broad Range Standard (catalog# 161-0318) was used as 
the general molecular weight ladder for all gels and samples were loaded at 1-30 µl per 
lane.  The gel was run using a Novex X-Cell SurelockTM Mini-Cell (Invitrogen) in 1X 
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Tris/glycine buffer (25 mM Tris, 250 mM glycine, 0.1% SDS).  The top, stacking phase, 
of the gel was run at 125 V and the bottom, separation phase, of the gel was run at 175 V 
with the Bio-Rad Model 200/2.0 power supply until the tracking dye reached the bottom 
of the cassette.  All gels were stained with Coomassie Brilliant Blue R-250 solution 
(0.1% Coomassie Brilliant Blue R-250, 40% methanol, 10% acetic acid) (Bio-Rad) for 30 
minutes to overnight, and then destained with 40% methanol, 10% acetic acid solution 
three times at 30 minutes per wash.  Alternatively, gels were subjected to western blot 
analysis as described below.   
 
3.  Blotting Procedure:   
 After the samples were run on an SDS-PAGE gel, a Bio-Rad Mini Trans-Blot® 
Electrophoretic Transfer Cell containing Trans-Blot Buffer (25 mM Tris, 192 mM 
glycine, 20% methanol, pH8.3) on ice was used to transfer the proteins from the gel to 
nitrocellulose paper (NitroBind, Cast, Pure Nitrocellulose, 0.45 Micron, 20 cm X 3 m, 
GE Water and Process Technologies, Fisher Scientific, Suwanee, GA).  The running 
conditions were set at 100 volts with a current maximum of 0.25 A for 23 minutes.  The 
membrane was then blocked for 25 minutes, while shaking, in Killer Filler buffer (10 g 
casein boiled in 200 ml 0.1 M NaOH added to 1.8 L Phosphate Buffer Saline [PBS; 5.3 L 
deionized water, 28 g NaCl, 0.7 g KCl, 4.0 g Na2HPO4, 0.35 g CaCl2-2H2O, 0.53 g 
MgCl2-6H2O] containing 10g bovine serum albumin, adjust pH to 7.4, add 0.2 g Phenol 
Red and 3.6 g sodium azide).  The primary antibody (dilution 10-2 or 10-3, see Table 3 
below) was incubated at room temperature for 5-12 hrs while shaking.  The blot was then 
washed three times with PBS for 10 min/wash.  The secondary antibody (10-3) was then 
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incubated at room temperature for 1 hour while shaking.  The blot was washed again 
three times with PBS for 10 min/wash.  If Fast-Red was used for visualization, an 
additional 10 minute wash step with 50 mM Tris/HCl pH8.0 was included.  Pilin proteins 
were probed with an alkaline phosphatase-labeled 2o antibody (Kirkegaard and Perry 
Laboratories, Gaithersburg, MD) and visualized using the Fast Red reaction mixture, 20 
mg Napthol AS-MX Phosphate (Sigma-Aldrich Co., St. Louis, MO) and 40 mg Fast-Red 
(Sigma-Aldrich Co.) dissolved in 20 ml 50 mM Tris/HCl pH8.0.  Alkaline phosphatase-
containing constructs were probed using a horseradish peroxidase-labeled 2o antibody 
(Kirkegaard and Perry Laboratories) and visualized with the SigmaFastTM 3,3-
diaminobenzidine tablet reaction mixture (catalog# D4418-5SET, Sigma-Aldrich Co.) or 
the SuperSignal® West Dura Extended Duration Substrate reaction (catalog# 34075, 
Pierce).   
 
 
 
Table 3.  Antibodies and Visualization 
1o Antibody  Dilution Description  Reference  
Anti-Bacterial Alkaline 
Phosphatase, Monoclonal  
1:1,000 Mouse derived  Sigma-Aldrich Co.   
Anti-E. coli Alkaline 
Phosphatase Polyclonal  
1:1,000 Rabbit derived  US Biomax, Inc., 
Ijamsville, MD 
Anti-P. Aeruginosa 1244 
O7-Antigen  Monoclonal, 
11.14 
1:1,000 Mouse derived  Sadoff et al., 1985  
Anti-P. aeruginosa 103 
O11-Antigen  
Monoclonal 
1:100 Mouse derived ERFA Biotech, 
Montreal (QC),  
Canada 
Anti-P. aeruginosa 1244 
Pilin Monoclonal, 5.44 
1:1,000 Mouse derived Castric & Deal, 1994 
Anti-P. Aeruginosa 683 
Pilin Polyclonal 
1:1,000 Mouse derived This study 
2o Antibody     
Phosphatase-labeled 
Anti-Mouse  
1:1,000 Goat derived, Affinity 
purified, Human serum 
adsorbed, visualized with 
the Fast Red reaction 
Kirkegaard and Perry 
Laboratories, 
Gaithersburg, MD 
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Phosphatase-labeled 
Anti-Rabbit  
1:1,000 Goat derived, Affinity 
purified, Human serum 
adsorbed, visualized with 
the Fast Red reaction 
Kirkegaard and Perry 
Laboratories, 
Gaithersburg, MD 
Peroxidase-labeled Anti- 
Mouse  
1:1,000 Goat derived, Affinity 
purified, Human serum 
adsorbed, visualized with 
the DAB reaction or 
Chemiluminescence 
Kirkegaard and Perry 
Laboratories, 
Gaithersburg, MD 
 
J.  Isoelectric Focusing  
Isoelectric focusing allowed assessment of the glycosylation status of mutated 
proteins by their isoelectric point-specific migration.  Addition of a glycan subunit may 
alter the isoelectric point of the protein and cause it to migrate differently on a gel in 
comparison to its native, non-glycosylated state.  Native cell fractions were prepared as 
above.  Prior to loading the protein samples, the gel (Amersham Biosciences Phast GelTM 
IEF 3-9, <0.2% acrylamide, Piscataway, NJ) was soaked in 1.5% n-octyl-β-D-
glucopyranoside (BOG), 3.4% ampholytes (AMP)3-9, 0.025% Azide for 15 minutes.  All 
protein samples were loaded in native conformation.  The standard marker was BIO-
RAD IEF pI 4.45-9.6.   Two microliters of each sample was touched to a comb that was 
used to load the gel.  The gel was run on a PhastSystem Separation and Control Unit 
under the separation command.   
Before the gel was finished running, a square of nitrocellulose paper was soaked 
in 50% methanol for 15 minutes.  This nitrocellulose paper was then used to capture the 
protein from the gel in a diffusion transfer process.  In this diffusion transfer of proteins 
from gel to the blotting paper, the gel was placed in a Petri dish and the nitrocellulose 
paper was placed on top of the gel (avoiding air bubbles).  The Petri dish was then sealed 
with plastic wrap and let sit at room temperature overnight.  The next day, the blotting 
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paper was peeled off of the gel and subjected to the routine Western blot development as 
above.   
 
K.  Generation of Polyclonal Anti-683 Pilin Antibodies 
  The current protocol, used to generate polyclonal antibodies against P. aeruginosa 
strain 683 pilin, was approved by Duquesne University’s Institutional Animal Care and 
Use Committee (IACUC).  All animal storage and experimentation took place at, the 
USDA approved, Duquesne University Animal Care Facility.   
 
1.  Antigen Preparation 
 Day 1:  P. aeruginosa strain 683 was grown up aerobically in LB broth overnight 
at 37oC, 250 rpm.  Metal culture pans (68 cm X 28 cm X 3 cm) and CAYE agar medium 
were sterilized in the autoclave.  One liter CAYE makes two pans at 500 ml per pan.   
 Day 2:  Sterilized CAYE culture pans were inoculated dropwise with 2.5-3.0 ml 
of PA683 overnight culture from Day 1, spread evenly over the surface of the pan with a 
sterile hockey stick, and incubated at 37oC for 14 hours.  
 Day 3:  After 14 hours at 37oC, the cells were harvested with a metal spatula and a 
sterile cotton swab into 100 ml CAYE broth.  The cells were completely resuspended by 
stirring vigorously for 30 minutes.  Pili were sheared from the cells by two excursions 
through a 50 ml syringe with an 18 gauge blunt end-needle.  Cells were divided into four 
50 ml centrifuge tubes (25 ml per tube) and centrifuged at 10,000 rpm for 30 minutes 
with a Sorvall®  SS-34 rotor. The supernatant was added to a 200 ml beaker and the pellet 
was discarded.  To the supernatant, 3% PEG (8,000) and 0.5 M NaCl was added and 
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stirred into solution at room temperature.  Once in solution, the suspension was stored on 
ice for 2 hours.  The suspension was then centrifuged again as earlier.  The supernatant 
was discarded and any remaining supernatant fluid was removed with a Kimwipe® 
(Kimberly-Clark, Dallas, Texas).  The pellets were resuspended in 100ml CAYE broth 
(total volume) and stirred for 1 hour at room temperature.  The suspension was 
centrifuged again as earlier. The pellet was discarded.  The supernatant was treated again 
with PEG to 3% and NaCl to 0.5 M and stirred at room temperature.  Once in solution, 
the suspension was stored on ice for 1 hour and then centrifuged again as earlier.  The 
supernatant was discarded and any remaining supernatant fluid was removed with a 
Kimwipe®.  The pellets were resuspended in 5 ml CAYE broth (total volume) and stored 
for 1 hour at room temperature.  This 5 ml suspension was divided into four 1.5 ml 
microfuge tubes (1.25 ml per tube) and microcentrifuged at 14,500 rpm (or at max) for 5 
minutes.  The pellets were discarded.  The supernatant was transferred to a new 1.5 ml 
microfuge tube and 250 µl of 15%PEG/2.5 M NaCl was added per 1,000 µl of 
supernatant.  The suspensions were mixed by vortexing and then incubated on ice for 30 
minutes.  Each sample was then microcentrifuged as 14, 500 rpm (or at max) for 10 
minutes.  The supernatant was drained completely and the pellets were stored at 4oC until 
they were resuspended in a total volume of 1,000 µl sterile deionized water.  At this point 
a polyacrylamide 16% T gel could be run and stained with Coomassie Brilliant Blue R-
250 solution to assess the purity of your pili preparation.   
 The pili suspension was dialyzed for 2 days in 6 liters of deionized water 
containing 1.5 g sodium azide stirring at 4oC.  The protein concentration of the dialyzed 
pili preparation was then determined by the Pierce BCATM Protein Assay Kit.  The 
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remaining pili preparation was lyophilized overnight and then resuspended with 
physiological saline solution (0.9% NaCl) to a concentration of 1 µg/µl.  The desired 
immunization concentration for each mouse was 10 µg antigen/100 µl.  To make the final 
working immunization stock for 8 mice, 80 µg/400 µl was prepared and taken up into a 
1cc glass syringe.  This glass syringe was then connected to another glass syringe 
containing 400 µl of Freund’s Incomplete Adjuvant (DIFCO Laboratories, Detroit, MI) 
by a stainless steel emulsifying needle.  The contents were mixed through the emulsion 
needle until a viscous equilibrated suspension was formed.  This prepared immunization 
stock suspension was then taken to the Duquesne University Animal Care Facility to 
immunize the mice.   
 
2.  Immunization 
 A total of 6 female Balb/C mice (Hilltop Lab Animals, Scottdale, PA), 
approximately 6-8 weeks old and weighing 25 g, were used for immunization.  The mice 
received a primary injection on day 1, followed by booster injections of the same 
concentration on days 7 and 14.  The mice were bled (described below) on day 21, 7 days 
after the final boost.  For all injections, the mice were anesthetized intraperitoneally using 
a 28-gauge needle with 250 µl ketamine HCL/xylazine HCL solution (6.67 mg ketamine 
HCL/mL; Ketaject® Pheonix Pharmaceutical Inc., St. Joseph, MO and 1.33 mg xylazine 
HCL/mL; Sigma® Sigma-Aldrich Co.).  A 22-gauge needle was used to immunize each 
mouse subcutaneously at the nape of the neck with 100 µl (10 mg antigen) of the 
emulsified antigen/adjuvant suspension.    
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3.  Serum Collection 
 The mice were anesthetized intraperitoneally using a 28-gauge needle with 250 ul 
ketamine HCL/xylazine HCL solution.  A 26-gauge tuberculin needle was used to harvest 
the blood by intra-cardiac puncture.  The blood was stored in 1.5 ml microfuge tubes at 
4oC for 1 hour and then microcentrifuged at 3,000 rpm for 1 minute.  The sera was drawn 
off and stored as 100 µl aliquots in 0.5 ml microfuge tubes.  The blood was then 
centrifuged a second time in a microcentrifuge at 5,000 rpm for 1 minute.  The sera, 
again, was drawn off and stored as 100 µl aliquots in 0.5 ml microfuge tubes.  The blood 
was centrifuged a third time at 5,000 rpm for 1 minute and stored as previously.  All 3 
rounds of sera were stored at -20oC until needed to prepare a working antibody dilution.  
Serum dilutions of 10-3 and 10-4 gave sufficient reactivity for use in immunoblot analysis. 
The dilution used in the present study can be found in Table 3. 
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III.  RESULTS 
 
 
 
A.  Homology Modeling and identification of surface properties of PA1244 PilA, 
PA683 PilA, and EC PhoA.  Previous findings have identified the necessity of a C-
terminal serine/threonine, a compatible surface charge surrounding this ultimate residue, 
and periplasmic localization for the glycosylation of pilin in PA1244 (Horzempa et al., 
2006a; Qutyan et al., 2008).  Homology modeling was performed on PA1244 PilA, 
PA683 PilA, and the E. coli (EC) K12 alkaline phosphatase homodimer to compare and 
contrast the tertiary structure of a known glycosylated protein, PA1244 PilA, to normally 
non-glycosylated proteins, PA683 PilA and EC PhoA (Figure 13).  Each of the 
engineered proteins in this study are known to localize to the periplasm, of which, the 
PA1244 PilA-EC PhoA fusion protein and the PA683 PilA protein, upon transfer by the 
pilin signal sequence, become embedded in the outer leaflet of the inner membrane 
(oriented in the periplasmic space), providing colocalization with the catalytic PilO 
protein to the site of glycosylation.  As highlighted by Comer et al.(2002) and Horzempa 
et al.(2006a), compatible characteristics of substrate glycosylation primarily encompass 
surface charge and location of the carboxy terminal serine residue (Figure 13).   In 2006, 
Horzempa et al. demonstrated that an electronegative surface charge was inhibitory to the 
glycosylation reaction, but could be side-stepped if the C-terminal serine residue was 
surfaced exposed and further extended away from the electronegative surface charge with 
a short spacer of alanine residues (Horzempa et al., 2006a).  The homology modeling 
revealed that the general surface charge of PA683 pilin and the bacterial alkaline 
phosphatase protein appear to be predominantly electropositive around the carboxy 
82 
terminal region, but more importantly, the C-terminal residues are surface exposed 
(Figure 13).  The general tertiary structure of the PA683 pilin was expected to similarly 
present a surface exposed carboxy terminal residue as the general model of pilin structure 
suggests (Craig et al. 2006; Horzempa et al. 2006; Keizer et al. 2001).  Each pilin 
possesses a characteristic, yet distinct, disulfide loop (DSL) region at their C-terminus 
(Figure 14) that has been previously ruled-out as a structural requirement for pilin 
glycosylation by necessity of surface charge, alone, in this region (Horzempa et al., 
2006a).  In attempt to nullify any surface incompatibilities, each construct was 
engineered by site-directed mutagenesis or by PCR to extend the C-terminal serine away 
from the surface by a minimum of two alanine residues or the C-terminal 15 amino acids 
of PA1244 pilin, of which the C-proximal cysteine residue was changed to an alanine 
(Figure 15).  Overall, these homology models reveal group III pilin and E. coli alkaline 
phosphatase to be attractive candidate proteins to be engineered for glycosylation, which, 
if successful, may hold practical application to the expansion of potential vaccine 
components.   
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Figure 13.  Predicted surface properties of PA1244 pilin monomer, PA683 pilin 
monomer, and E. coli alkaline phosphatase homodimer.  Tertiary structures of each 
were generated by homology modeling.  Whole structure models have the C-terminal 
amino acid residue highlighted yellow and labeled with an arrowhead.  Zoomed images 
have the C-terminal amino acid residue highlighted in yellow and display surface charge 
properties, respectively.  For surface charge; blue indicates a positive charge, red 
indicates a negative charge, and white indicates neutral charge.   
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Figure 14.  Disulfide loop regions of PA1244 pilin and PA683 pilin.  Cysteine residues 
are in red and underlined.  Conserved residues of the DSL region are in red.   
 
 
 
 
Figure 15.  C-terminal peptide extensions used to study glycosylation substrate 
specificity of P. aeruginosa.  The C-terminus with the entire disulfide loop amino acid 
sequence is given for PA1244 pilin.  The disulfide bond forming cysteine residues are 
underlined for PA1244 pilin and PA683 pilin.  The alanine substitution is underlined for 
PA683 PilA-Pep.  C-terminal extensions added to each construct are highlighted in blue.  
The linker region for the PA1244 pilA-EC phoA fusion is highlighted in red.  Residue 
specifications are in parenthesis.   
 
 
 
B.  Can a structurally different, Group III, pilin be engineered to accept the O-
antigen repeating unit of lipopolysaccharide? 
Is PA683 pilin already being modified?  Before assessing whether pilin from strain 
PA683 could be engineered for glycosylation, I first needed to determine whether or not 
this pilin is already being modified.  Preliminary data from the Castric laboratory 
demonstrated that, although the gene sequence of PA683 pilA (540 nucleotides) is larger 
than Group I PA1244 pilA (465 nucleotides), PA683 pilin runs at a lower apparent 
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molecular weight on an SDS-PAGE gel, suggesting an unknown characteristic of tertiary 
structure (personal communication, with M. C. Quinn).  Mature unglycosylated PA1244 
pilin has a theoretical molecular weight of 15,640 Daltons (Da), an apparent molecular 
weight on SDS-PAGE of about 15,600 Da (Castric, 1995), and an actual molecular 
weight of 16,307 Da as determined by MALDI analysis (Castric et al., 2001).  MALDI 
analysis also revealed the size of the glycan subunit to be about 666 Da (Castric et al., 
2001).  With this covalently attached glycan, mature glycosylated PA1244 pilin migrates 
to an apparent molecular weight of 16,900 Da on SDS-PAGE, and was determined by 
MALDI analysis to be about 16,973 Da (Castric et al., 2001).  For these two flavors of 
PA1244 pilin, molecular weight analysis by SDS-PAGE yields fairly accurate 
approximations.   
SDS-PAGE was performed on purified PA683 pilin to determine the apparent 
molecular weight value for comparison to the theoretical and known values.  The 
theoretical molecular weight of PA683 pilin is 17, 439 Da.  This predicted value agrees 
with the mass of PA683 pilin generated by MALDI-TOF (17,475 Da) (personal 
communication, with P.A. Castric).  Although the predicted/determined molecular weight 
of PA683 pilin is larger than that of PA1244 pilin, preliminary SDS-PAGE analysis 
demonstrated that PA683 pilin migrates to a surprisingly smaller size than glycosylated 
PA1244 pilin (16,900 Da).  This SDS-PAGE analysis was repeated in the current study 
and the same result was reproduced (Figure 16A).  Pooled standard curve estimations 
from several gels suggest PA683 pilin migrates to about 15,000-16,300 Da, which is less 
than the predicted weight of 17,439 Da and MALDI-TOF generated mass of 17,475 Da 
(Figure 16A).  These findings suggest that strain PA683 pilin is not posttranslationally 
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modified.  The unexpected migration of this protein on an SDS-PAGE gel may be the 
result of incomplete protein unfolding in the presence of this detergent.     
Although MALDI analysis of PA683 pilin has indicated no significant mass deviation 
from the theoretical value, the role of group III accessory protein, TfpY, in 
posttranslational modification of PA683 pilin was further explored.  In 1995, Castric 
showed that the PilO accessory protein was necessary for the posttranslational 
glycosylation of PA1244 pilin (Castric, 1995).  The pilO gene is located between the 
gene sequences of pilA and tRNAthr in the operon of P. aeruginosa strains that produce 
Group I pilin.  P. aeruginosa strains that possess group III pilin, such as PA683, have the 
ORF of a suspected non-homologous accessory protein, TfpY, of unknown function in 
place of the pilO gene (Figure 8).  To identify a potential role of TfpY in the 
posttranslational alteration of PA683 pilin size, the gene sequences of pilA and pilA-tfpY 
were cloned into a pMMB66EH vector and overexpressed in a strain of P. aeruginosa 
that does not express pilAO, PA1244N3, to produce p683pilA and p683pilA-tfpY.  
Overexpressed pili were sheared from the cells and subjected to SDS-PAGE analysis 
(Figure 16B).  The SDS-PAGE results showed all PA683 pilin bands migrated to the 
same size, which suggests that TfpY does not confer a modification that noticeably alters 
pilin size by this technique.   
Next, an electrofocusing gel of purified pili from PA1244N3/p683pilA and 
PA1244N3/p683pilA-tfpY was used to determine whether TfpY is required for altering 
the charge of mature pilin (Figure 16C).  The predicted isoelectric point (pI) of PA683 
pilin is about 4.45.  All pilin bands on the gel migrated to this theoretical pI, indicating 
that TfpY does not attribute an identifiable charge altering modification to pilin (Figure 
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16C).  Collectively, these findings do not identify detectable molecular alterations to 
PA683 pilin by TfpY and are consistent with the MALDI results that suggest PA683 pilin 
is not modified.   
 
Figure 16.  Molecular weight and electrofocusing-based polyacrylamide gel analysis 
of PA683 pilin for modification by TfpY.  Sixteen percent T gel demonstrating a 
molecular weight comparison of glycosylated wild type P. aeruginosa 1244 pilin and 
wild type PA683 pilin (A).  Sixteen percent T gel demonstrating a molecular weight 
comparison of purified PA683 pilin produced by P. aeruginosa 683 and IPTG-induced P. 
aeruginosa 1244N3/p683pilA-tfpY, PA1244N3/p683pilA, and PA1244N3/pMMB66EH 
(empty vector) (B).  Isoelectric focusing gel of purified PA683 pilin produced by PA683 
and IPTG-induced PA1244N3/p683pilA-tfpY, PA1244N3/p683pilA, and 
PA1244N3/pMMB66EH (C).   
 
 
Can PA683 pilin be engineered for glycosylation?  Strain PA683 pilin was classified as 
group III on the premise of sequence homology with known group III pilins (i.e. PA14) 
and presence of the adjacent tfpY ORF (unpublished observation; Kus et al., 2004).  
Although the general tertiary structure of pilins are conserved, structural differences can 
be identified between groups within the DSL and α-β loop regions.  These differences can 
be observed between PA1244 and PA683 pilins in Figure 13.  As mentioned, previous 
findings indicate that the normally non-glycosylated PA103 group II pilin can be 
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engineered for glycosylation in PA1244 by extending a C-terminal serine away from the 
inhibitory electronegative surface with a short stretch of alanine residues (Horzempa et 
al., 2006a).  To determine whether the normally non-glycosylated PA683 group III pilin 
could be engineered for glycosylation, an alanine-alanine-serine (A-A-S) peptide 
extension was added to the C-terminal arginine residue and cloned into pMMB66EH, 
forming p683aas.  This construct was transformed into a mutant PA103-derived strain 
that does not polymerize LPS surface O-antigen, PA103 wzyPaO11::aacC1, along with a 
pUCP26 vector containing the O-transferase responsible for glycosylation of pilin in 
PA1244, pilO (pUCP26 pilO).  Control strains were transformed with the empty pUCP26 
vector.  PA103 wzyPaO11::aacC1 eliminates the presence of the LPS ladder on an anti-O-
antigen immunoblot.  Plate grown P. aeruginosa cells are known to increase piliation 
(Silipigni-Fusco, 1987).  When whole cell extracts of plate grown strains were subjected 
to Western blot analysis, the C-terminal A-A-S peptide extension was demonstrated to be 
sufficient for the glycosylation of PA683 pilin (Figure 17A).  This was determined by 
mutant pilin migration on SDS-PAGE probed with a polyclonal antibody specific for 
PA683 pilin (Figure 17A), and by an antibody specific for the PA103 O11 O-antigen 
glycan (Figure 17B).  The low yield of glycosylated mutant pilin compared to the 
PA1244 glycosylated control pilin suggests the construct may be unstably produced or 
that glycosylation efficiency is low with this particular mutant.  These findings indicate 
that group III pilin monomers can be engineered for glycosylation with this minimal 
glycosylation substrate.   
There are a series of bands on the anti-PA683 pilin blot that can be explained.  In the 
lane containing p683aas/pilO, the top band is glycosylated mutant pilin, the second band 
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down is unglycosylated mutant pilin, the third band down is believed to be PA683 pilin 
with the A-A-S peptide extension cleaved off due to its alignment with control PA683 
pilin band, and the lighter bands below this are thought to be more advanced degradation 
of the mutant PA683 pilin monomer.  In addition to the glycosylated mutant pilin band, 
there are two additional bands on the blot probed with anti-O11 that can be explained.  In 
the lane containing p683aas/pilO, the two bands at the bottom of the gel are an artifact of 
the PA103 wzyPaO11::aacC1 system.  The lower band is lipid A and the higher band is 
core plus one O-antigen subunit.  As mentioned, this results because the wzy mutant does 
not polymerize additional LPS O-antigen subunits.  These same bands should have also 
been observed in the lanes containing p683aas/pUCP26 and pPAC24/pilO, however, the 
reaction does not appear as strong.   
 To determine whether a pilin specific sequence would increase glycosylation 
efficiency in this PA103 wzyPaO11::aacC1 system, the 15 C-proximal amino acids of 
PA1244 pilin (with the C-proximal cysteine changed to an alanine) were added to the C-
terminal arginine residue of PA683 pilin and cloned into pMMB66EH, forming p683pep.  
This peptide tail mutation has been previously shown to be a major B-cell epitope of 
PA1244 pilin (Castric & Deal, 1994).  The p683pep construct was transformed into 
PA103 wzyPaO11::aacC1 in the presence and absence of PilO expression, and whole cell 
extracts of plate grown cells were subjected to Western blot analysis.  Western blot 
analysis confirmed the glycosylation of mutant pilin by migration on SDS-PAGE probed 
with a polyclonal antibody specific for PA683 pilin (Figure 17A), and by detection with 
an antibody specific for the PA103 O-antigen (Figure 17B).  The low yield of 
glycosylated mutant pilin compared to the PA1244 glycosylated control pilin suggests the 
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construct may be unstably produced or that glycosylation efficiency is low with this 
particular mutant.  This finding indicated that addition of a pilin-specific glycosylation 
site permits glycosylation of group III pilin, but does not appear to greatly increase 
glycosylation efficiency in this system.   
There are a series of bands on the blot probed with anti-PA683 pilin that can be 
explained.  In the lane containing p683pep/pilO, the top band is glycosylated mutant 
pilin, the second band down is unglycosylated mutant pilin, the third band down is 
believed to be PA683 pilin with the peptide tail mutation partially cleaved off due to its 
slight offset al.ignment with control PA683 pilin band, and the lighter bands below this 
are thought to be more advanced degradation of the mutant PA683 pilin monomer.  In 
addition to the glycosylated mutant pilin and control bands, lipid A and core plus one O-
antigen subunit bands can be observed as in Figure 17B.   
 Although previous findings suggested that glycosylation of pilin does not appear 
to have an effect of pilus biogenesis (Smedley et al., 2005), functional assays were 
performed to determine if heterologously expressed group III pilin and the respective 
mutant epitopes are compatible with the PA1244 pilus biogenesis machinery.  When pilin 
is overexpressed from p683pilA in the pilAO null strain, PA1244N3, surface pili and 
twitching motility are observed (personal communication, with P.A. Castric).  However, 
when both mutant PA683 pilins are separately overexpressed from p683aas and p683pep 
in PA1244N3, surface pili and twitching motility are absent (personal communication, 
with P.A. Castric).  These findings suggest that wild type PA683 pilin is tolerated by 
PA1244 pilus machinery while each mutation prohibits pilus biogenesis.   
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Figure 17.  Western blot analysis of mutant PA683 pilins expressed in PA103 
wzyPaO11::aacC1.  Western blot of PA683 pilin produced by IPTG-induced PA103 
wzyPaO11::aacC1/p683aas  and PA103 wzyPaO11::aacC1/p683pep whole cell extracts in the 
presence of PilO (pUCP26pilO) and in the absence of PilO (pUCP26) using anti-PA683 
pilin polyclonal antibody as a probe (A) or anti-O11 monoclonal antibody as a probe (B).  
Purified wild type PA683 pilin served as a positive control for the anti-PA683 pilin 
antibody probe and heterologously glycosylated PA1244 pilin (pPAC24/pilO) served as a 
positive control for the anti-O11 antibody probe.  A whole cell extract of wild type 
PA103 was run to show that there is no cross-reactivity of the PA683 pilin polyclonal 
antibody with PA103 pilin.  PA103 wzyPaO11::aacC1/p683pilA/pilO was used as a 
positive control for the anti-PA683 pilin blot, and as a negative control for the anti-O11 
glycan blot.   
 
 
 
C.  Can a protein fused to pilin be engineered to accept the O-antigen repeating unit 
of lipopolysaccharide?  Although Horzempa et al. (2006a) demonstrated a lack of C-
proximal consensus residues, other than serine/threonine, for pilin glycosylation, 
additional structural characteristics, such as anchorage to the inner cell membrane via 
hydrophobic tail residues, may be necessary for PilO substrate recognition.  To examine 
this, the PA1244 structural pilin gene, pilA, was fused inframe at the 27th amino acid 
encoding codon of an E. coli alkaline phosphatase gene via the fusion vector pRMCD28, 
to form pPilAPhoA.  Expression of this construct was first assessed in E. coli (Figure 
18).  Whole cell extracts of a strain containing pPilAPhoA were subjected to Western 
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blot analysis and probed with a monoclonal anti-bacterial alkaline phosphatase (BAP) 
antibody (Figure 18A) and a monoclonal anti-PA1244 pilin antibody, 5.44 (Figure 18B).  
The fusion was successfully expressed and detected on each blot at the expected 
molecular weight of about 63.5 kDa, noticeably larger than the E. coli PhoA control band 
(~47 kDa) (Figure 18).  The intact fusion is believed to be the single predominant band 
on both blots.  The other bands in the anti-BAP blot fusion lane are believed to be 
incomplete denaturation (above fusion band) and degradation (below fusion band).   
 
Figure 18.  Western blot analysis of PA1244 PilA-EC PhoA fusion expressed in E. 
coli.  Western blot of IPTG-induced PA1244 PilA-EC PhoA fusion protein (pPilAPhoA), 
the empty fusion vector (pRMCD28), and an E. coli alkaline phosphatase control protein 
(pHK734) produced by E. coli HB101 cell extracts using anti-BAP monoclonal antibody 
(A) or anti-PA1244 pilin monoclonal antibody 5.44 (B) as a probe.  A whole cell extract 
of HB101 without a vector was used as an additional negative control to show that 
endogenous alkaline phosphatase did not react with the anti-BAP monoclonal antibody 
(A).  Purified glycosylated PA1244 pilin was used as a positive control for the 5.44 
antibody (B).   
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To determine whether a PA1244 PilA- EC PhoA fusion protein can be engineered 
for glycosylation, an A-A-S peptide extension was added to the C-terminal lysine residue 
of PhoA and cloned into pMMB66EH, forming pPilAPaas.  Two P. aeruginosa systems, 
PA1244 and PA103 wzyPaO11::aacC1, were used to assess the glycosylation status of a 
fusion protein engineered with a minimally pilin-compatible PilO-recognition site (A-A-
S).  The PA1244 system was used first because it is the model strain for O-linked pilin 
glycosylation.  The PA103 wzyPaO11::aacC1 system was then utilized because it 
eliminated LPS-band contamination on Western blots probed with anti-O-antigen 
antibody.  As mentioned, previous results from the Castric laboratory suggest the 
necessity of a C-terminal surface exposed serine residue as the sole acceptor of the glycan 
subunit (Horzempa et al., 2006a).  All non-terminal serine residues are unable to accept a 
glycan modification, eliminating the potential for serine residues within the fusion 
peptide sequence to be glycosylated, which would result in a false positive.  Functional 
periplasmic alkaline phosphatase activity was recorded for all alkaline phosphatase 
containing constructs in both systems, PA1244 and PA103 wzyPaO11::aacC1 (Table 4).  
This demonstration of periplasmic functionality suggests that alkaline phosphatase is able 
to achieve a functional conformation and that the prepilin leader sequence is able to 
successfully target the fusion to the periplasmic face of the inner cell membrane.  
Because PA1244 pilin is known to become embedded in the inner cell membrane, 
insoluble (IS) fractions of cell extracts prepared from plate grown PA1244/pPilAPaas and 
PA1244/pMMB66EH were subjected to Western analysis.  Western blot results show that 
the mutated fusion was not glycosylated based on migration on SDS-PAGE probed with 
anti-bacterial alkaline phosphatase (BAP) (Figure 19A), and by the lack of a reaction 
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with an anti-O7 antibody, 11.14 (Figure 19B).  The same result was observed when the 
blot was re-run and visualized with the more sensitive chemiluminescence technique 
(Figure 20).  These results indicate an inability of the A-A-S peptide extension to tag a 
PA1244 PilA-EC PhoA fusion protein for glycan acceptance using the native 
physiological glycosylation mechanism of PA1244.   
On the anti-BAP blot of Figure 19A, the faint bands in the control IS fraction 
PA1244/pMMB66EH lane resulted from sample spill-over from the IS 
PA1244/pPilAPaas lane.  Additionally, in Figure 19B and Figure 20B, the ladder 
banding pattern can be attributed to anti-O11 antibody reaction with LPS.  The detection 
of LPS ladder may make it difficult to identify a glycosylated band of a given molecular 
weight.  In the present case, the fusion bands migrate to a higher molecular weight than 
the largest detectable LPS band, eliminating ambiguity.  The PA103 wzyPaO11::aacC1 
system was used to eliminate the appearance of an LPS ladder on anti-glycan probed 
blots.  
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Figure 19.  Western blot analysis of mutant PA1244 PilA-EC PhoA fusion expressed 
in PA1244.  Western blot of soluble (S) and insoluble (IS) fractions of IPTG-induced 
PA1244/pPilAPaas and PA1244/pMMB66EH (empty vector) for mutant PA1244 PilA-
EC PhoA-AAS fusion protein using anti-BAP monoclonal antibody as a probe (A) or 
anti-O7 monoclonal antibody 11.14 as a probe (B).  Purified glycosylated PA1244 pilin 
was used as a positive control for the 11.14 antibody (B).      
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Figure 20.  Chemiluminescent blot analysis of mutant PA1244 PilA-EC PhoA fusion 
expressed in PA1244.  Chemiluminescent blot of IS cell fractions of IPTG-induced 
PA1244/pPilAPaas and PA1244/pMMB66EH (empty vector) for mutant PA1244 PilA-
EC PhoA-AAS fusion protein using anti-BAP monoclonal antibody as a probe (A) and 
anti-O7 monoclonal antibody 11.14 as a probe (B).  Purified glycosylated PA1244 pilin 
was used as a control for the 11.14 antibody (B).   
 
 The original and mutated fusion constructs were then transformed into  
PA103 wzyPaO11::aacC1 in the presence of PilO, and whole cell extracts prepared from 
broth grown cells were subjected to Western blot analysis (Figure 21).  Unpublished 
observations have indicated near identical glycosylation efficiency in broth and plates 
with this strain.  Western blot analysis in this system also demonstrated that the mutated 
fusion was not glycosylated based on migration on SDS-PAGE probed with anti-BAP 
(Figure 21A) and anti-PA1244 pilin (5.44) (Figure 21B), and by the lack of detection 
with an anti-O11 antibody (Figure 21C).  These results indicate an inability of the A-A-S 
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peptide extension to serve as a compatible site for fusion glycan acceptance in the PA103 
wzyPaO11::aacC1 glycosylation system.   
The anti-BAP and 5.44 blots indicate that the original fusion has a slightly higher 
molecular weight, which may be due to degradation of the mutant fusion (Figure 
21A&B).  PhoA degradation appears evident by the presence of two lower weight bands 
on the anti-BAP blot in the lanes of both, original and unmutated, fusion proteins (Figure 
21A).  However, the 5.44 blot does not show detection of these degradation products, 
indicating that the 5.44 immunological epitope of PA1244 pilin is being cleaved from the 
fusion (Figure 21B).  Additionally, the bands observed in the anti-O11 blot (Figure 21C) 
around 38-40 kDa are unknown, yet established artifacts of this probe, and the absence of 
lipid A and core plus one O-antigen bands are attributed to running off of the 
polyacrylamide gel during electrophoresis.  Overall, this glycosylation incompatibility in 
both systems, PA1244 and PA103 wzyPaO11::aacC1, suggests that PilO may require a yet 
unestablished degree of proximity or accessibility to pilin-specific structures.   
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Figure 21.  Western blot analysis of mutant PA1244 PilA-EC PhoA fusion expressed 
in PA103 wzyPaO11::aacC1.  Western blot of IPTG-induced PA103 
wzyPaO11::aacC1/pPilAP and PA103 wzyPaO11::aacC1/pPilAPaas for PA1244 PilA-EC 
PhoA and mutant PA1244 PilA-EC PhoA-AAS fusion proteins in the presence of PilO 
(pUCP26pilO) using anti-BAP monoclonal antibody as a probe (A), anti-PA1244 pilin 
monoclonal antibody 5.44 (B),  or anti-O11 monoclonal antibody (C) as a probe.  Whole 
cell extracts of PA103 and HB101 cultured with phosphate-limited (PL) media were used 
as controls for anti-BAP monoclonal antibody (A).  Whole cell extract of IPTG-induced 
PA103 wzyPaO11::aacC1/pPAC24/pilO was used as a control for 5.44 (B) and anti-O11 
(C).   
 
 
Strain PhoA Units
PA1244/pMMB66EH 0.0 
PA1244/pECAP 2,756.1 
PA1244/pECAPaas 1,772.3 
PA1244/pPilAPaas 2,121.5 
 
Strain PhoA Units
PA103 wzyPaO11::aacC1/pilO/pPAC24 0.0 
PA103 wzyPaO11::aacC1/pilO/pECAP 15,629.2 
PA103 wzyPaO11::aacC1/pilO/pECAPaas 20,569.1 
PA103 wzyPaO11::aacC1/pilO/pPilAP 11,506.6 
PA103 wzyPaO11::aacC1/pilO/pPilAPaas 11,836.4 
Table 4.  Periplasmic phosphatase activity of alkaline phosphatase constructs in 
PA1244 and PA103 wzyPaO11::aacC1 strain backgrounds.   
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D.  Can a non-pilin protein be engineered to accept the O-antigen repeating unit of 
lipopolysaccharide?  Although the fusion protein was unable to be engineered for 
glycosylation, the necessity of pilin specific structures was further pursued by attempting 
to glycosylate E. coli alkaline phosphatase not fused to PA1244 pilin.  To determine 
whether the E. coli alkaline phosphatase protein can be engineered for glycosylation, an 
A-A-S peptide extension was added to the C-terminal lysine residue of PhoA and cloned 
into pMMB66EH, forming pECAPaas.  Expression of this construct was first assessed in 
E. coli.  Whole cell extracts of HB101/pECAPaas were subjected to Western blot 
analysis probed with a monoclonal anti-BAP antibody (Figure 22).  The mutated PhoA 
was successfully expressed and detected on the blot at the expected molecular weight of 
about 47.4 kDa (Figure 22).  As observed in the lanes containing unmutated PhoA 
(pHK734, pECAP) and mutated PhoA (pECAPaas), when these constructs are 
overexpressed, they were observed as two closely stacked bands.  The faint bands below 
were thought to be further degradation products of PhoA.  This banding pattern can be 
seen when expressed in all strains (HB101, PA1244, and PA103 wzyPaO11::aacC1).   
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Figure 22.   Western blot analysis of mutant E. coli alkaline phosphatase in E. coli.  
Western blot of IPTG-induced HB101/pECAP, and HB101/pECAPaas whole cell 
extracts for EC PhoA and mutant EC PhoA-AAS proteins using anti-BAP monoclonal 
antibody as a probe. A whole cell extract of IPTG-induced HB101/pHK734 was used as a 
positive control for wild type PhoA expression and the anti-BAP antibody.  A whole cell 
extract of HB101 without a vector was used as an additional negative control to show that 
endogenous alkaline phosphatase did not react with the anti-BAP monoclonal antibody.   
 
 Again, two P. aeruginosa systems, PA1244 and PA103 wzyPaO11::aacC1, were 
used to assess the glycosylation status of an E. coli PhoA protein engineered with a 
minimally pilin-compatible PilO-recognition site (A-A-S).  The PA1244 system was used 
first because it is the model strain for O-linked pilin glycosylation.  The PA103 
wzyPaO11::aacC1 system was then utilized because it eliminated LPS-band contamination 
on Western blots probed with anti-O-antigen antibody.  Functional periplasmic alkaline 
phosphatase activity was recorded for all alkaline phosphatase containing constructs in 
both, PA1244 and PA103 wzyPaO11::aacC1, systems (Table 4).  This demonstration of 
periplasmic functionality suggests that alkaline phosphatase is able to be targeted to the 
periplasmic space by its signal sequence in P. aeruginosa and achieve a functional 
conformation.  Because PhoA is known to localize to the periplasmic space, periplasmic 
fractions (PF) of plate grown PA1244/pECAPaas and PA1244/pECAP strains were 
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subjected to Western blot analysis.  Western blot results show that the mutated PhoA was 
not glycosylated based on migration on SDS-PAGE probed with anti-BAP (Figure 23A), 
and by lack of a reaction with an anti-O7 antibody (11.14) (Figure 23B).  However, the 
detection of LPS ladder in the anti-O7 blot of Figure 23B made identification of a 
glycosylated PhoA band difficult.  The PA103 wzyPaO11::aacC1 system was used later to 
eliminate this problem.   
 
Figure 23.  Western blot analysis of mutant E. coli alkaline phosphatase in PA1244.  
Western blot of pellet and periplasmic fractions (PF) of IPTG-induced PA1244/pECAP 
and PA1244/pECAPaas for EC PhoA and mutant EC PhoA-AAS proteins using anti-
BAP monoclonal antibody as a probe (A) and anti-O7 monoclonal antibody 11.14 as a 
probe (B).  Purified glycosylated PA1244 pilin was used as a control for 11.14 (B).  S and 
IS fractions of IPTG-induced PA1244/pMMB66EH were used as negative controls for 
both antibodies.   
 
Periplasmic fractions of plate and broth grown PA1244/pECAPaas were subjected 
to protein separation by electrofocusing and subsequent immunoblot analysis (Figure 
24).  The O7 glycan is known to be acidic.  Covalent addition of the O7 glycan to 
mutated PhoA would cause it to migrate to a more acidic isoelectric point on the pH-
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based gel.  The mutation, A-A-S, itself, is not expected to alter migration because alanine 
and serine are uncharged.  Immunoblot analysis of electrofocused protein extracts using 
an anti-BAP antibody (Figure 24A) demonstrated no deviation of migration pattern 
between mutated and unmutated PhoA, suggesting mutant PhoA is not glycosylated.  The 
multiple bands observed in this blot were thought to be migration of degradation 
products.  The possibility of these bands being glycosylated was ruled out because they 
were consistent between mutated and unmutated fractions and they do not appear in the 
11.14 blot.  Immunoblot analysis of electrofocused PhoA proteins using 11.14 
(Figure24B) demonstrated no reaction with the anti-O7 antigen, again, suggesting mutant 
PhoA was not glycosylated.  The smear at the bottom of the 11.14 blot was thought to be 
an artifact of handling the blot or from minimal LPS contamination.  These results 
indicate an inability of the A-A-S peptide extension to tag the PhoA protein for glycan 
acceptance using the native physiological glycosylation mechanism of PA1244.   
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Figure 24.  Isoelectric focusing analysis of mutant E. coli alkaline phosphatase in 
PA1244.  Immunoblot of electrofocused periplasmic fractions containing ECAP and 
ECAP-AAS produced by IPTG-induced plate grown PA1244/pECAP, plate grown 
PA1244/pECAPaas, and broth grown PA1244/pECAPaas using anti-BAP monoclonal 
antibody as a probe (A) and anti-O7 monoclonal antibody 11.14 as a probe (B).  Purified 
glycosylated PA1244 pilin was used as a control for 11.14 (B) 
 
 
 The unmutated and mutated PhoA constructs were then transformed into PA103 
wzyPaO11::aacC1 in the presence of PilO, and broth grown whole cell extracts were 
subjected to Western blot analysis (Figure 25).  Western blot analysis in this system also 
demonstrated that mutated PhoA was not glycosylated based on migration on SDS-PAGE 
probed with anti-BAP (Figure 25A), and by the lack of detection with an anti-O11 
antibody (Figure 25B).  These results indicate an inability of the A-A-S peptide 
extension to serve as a compatible site for PhoA glycan acceptance in the  
PA103 wzyPaO11::aacC1 glycosylation system.  The anti-BAP blot indicates that the 
mutated PhoA has a slightly higher molecular weight (Figure 25A).  The bands observed 
104 
in the anti-O11 blot (Figure 25B) around 38-40 kDa are unknown, yet established 
artifacts of this probe, and the absence of lipid A and core plus one O-antigen bands are 
attributed to running off of the polyacrylamide gel during electrophoresis.  Overall, this 
glycosylation incompatibility in both, PA1244 and PA103 wzyPaO11::aacC1, systems 
suggests the requirement for pilin-specific structures or a longer peptide extension, such 
as the highly antigenic peptide tail that was engineered on the PA683 pilin above.   
 
 
Figure 25.  Western blot analysis of mutant E. coli alkaline phosphatase in PA103 
wzyPaO11::aacC1.  Western blot of IPTG-induced PA103 wzyPaO11::aacC1/pECAP and 
PA103 wzyPaO11::aacC1/pECAPaas cell extracts for EC PhoA and mutant EC PhoA-AAS 
proteins in the presence of PilO (pUCP26pilO) using anti-BAP monoclonal antibody as a 
probe (A) and anti-O11 monoclonal antibody as a probe (B).  Whole cell extracts of 
PA103 and HB101 cultured with phosphate-limited (PL) media were used as controls for 
anti-BAP monoclonal antibody (A).  Whole cell extract of IPTG-induced  
PA103 wzyPaO11::aacC1/pPAC24/pilO was used as a control for anti-O11 (B).   
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IV.  DISCUSSION 
 
 
 
 Glycosylation is a posttranslational modification of protein that has been observed 
in eukaryotes, archea, and prokaryotes (Abu-Qarn et al., 2008).  Two types of 
glycosylation have been identified, N-linked and O-linked.  N-linked glycosylation 
occurs when a saccharide modification is covalently linked to the amide nitrogen of an 
asparagine side chain.  N-glycosylation generally occurs at a conserved consensus 
sequence (AsnXxxSer/Thr/Cys, where X and x are any amino acid except proline) and 
has been reported in eukaryotes, archea, and prokaryotes.  O-linked glycosylation occurs 
when a saccharide is covalently linked to the hydroxy oxygen of a serine or threonine 
side chain.  O-glycosylation has been shown to occur in eukaryotes and prokaryotes with 
no known consensus sequence identified to date.  Interestingly, the study of protein 
glycosylation in prokaryotes has identified a high incidence of this posttranslational 
modification in mucosal pathogens such as Campylobacter jejuni, Helicobacter pylori, 
Neisseria gonorhoeae, N. meningitidis, and P. aeruginosa (Szymanski & Wren, 2005; 
Abu-Qarn et al., 2008).  Although the specific role of glycosylation in these bacterial 
pathogens is still unclear, studies have demonstrated that abololition of glycosylation has 
resulted in diminished ability to survive within a host (Szymanski et al., 2002; 
Hendrixson & DiRita, 2004; Arora et al., 2005; Smedley et al., 2005; Szymanski & 
Wren, 2005; Abu-Qarn et al., 2008).  Additionally, prokaryotic glycosylation systems 
have been shown to utilize saccharide residues distinct from those utilized in eukaryotic 
glycosylation (Abu-Qarn et al., 2008).  These two findings appeal to the generation of 
bioconjugate vaccines targeting the glycan modification.   
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If a glycan is used as a target of vaccination, it would ideally be conjugated to a 
highly immunogenic peptide.  The mechanism of glycosylation in PA1244 is very 
appealing to vaccine design because PilO utilizes preassembled LPS O-antigen subunits 
to glycosylate the highly immunogenic pilin protein, thereby stimulating host immune 
defenses to pilin, glycan, and LPS surface layer of gram-negative pathogens.  Current 
cross linking methods allow normally non-glycosylated proteins such as toxoids to serve 
as the protein conjugate to glycan units.  The goal of the current research was determine 
whether or not normally non-glycosylated proteins could be engineered for glycosylation 
in vivo by exploiting the O-glycosylation machinery of P. aeruginosa.   
 
A.  The role of TfpY as a group III pilin accessory protein.  MALDI-TOF analysis in 
conjunction with SDS-PAGE and electrofocusing reveal that PA683 pilin is not modified, 
and therefore, TfpY confers no direct modification to this surface protein.  The unusual 
migratory pattern of PA683 pilin on SDS-PAGE is interpreted to result from the inability 
of SDS detergent to completely denature the pilin protein—although other detergents 
were not tested.  The hydrophobicity of SDS may not be able to disrupt hydrophobic 
residues of the α-helix tail causing the pilin to migrate to a molecular weight lower than 
expected.  Recently, Asikyan et al. (2008) have identified a role for TfpY in pilin 
polymerization.  Specifically, they showed that complementation of a PAO1 pilA mutant 
with pilA-tfpY, from group III strain PA14, could restore twitching motility and 
recoverable surface pili, but complementation with pilA alone could not restore these 
phenotypes.  Their results also suggested an antagonistic role to PilT, an accessory 
protein known to be involved in pilus retraction (Asikyan et al., 2008).  However, results 
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from the Castric laboratory disagree with these findings.  Complementation of the pilAO 
mutant, PA1244N3, with PA683 pilA, alone, was able to restore twitching motility 
(personal communication, with P.A. Castric) and surface pili.  Although band intensity 
was not quantified for significance, the surface pili in Figure 16B suggests TfpY has no 
effect on polymerization.  In this figure, complementation with PA683 pilA and PA683 
pilA-tfpY appeared to yield comparable amounts of surface pili.  As future work, the role 
of TfpY as a pilin accessory protein should continue to be pursued.   
 
B.  Glycosylation of Group III pilin engineered with C-terminal peptide extensions.  
Western blot analysis showed that both, -AAS and peptide tail, extensions permitted the 
larger, more hydrophobic PA683 pilin to be glycosylated in P. aeruginosa.  These 
findings, along with similar results with mutant PA103 pilins, suggest pilin-specific 
recognition by PilO (Horzempa et al., 2006a; personal communication, with M. Qutyan).  
However, each of the engineered PA683 pilin mutants yielded minimal reaction with 
primary antibody upon immunoblotting, which indicates that the ability to produce 
glycosylated PA683 pilin is less efficient then native group I (PA1244) pilin or group II 
(PA103 mutants) pilin (Horzempa et al., 2006a; personal communication, with P. A. 
Castric & M. Qutyan).  Inefficiency of glycosylation may be directly related to pilin-
specific properties such as surface charge, as indicated by Horzempa et al. (2006a).  
Horzempa et al. (2006a) identified a significant difference in DSL charges of PA1244 
pilin (pH 9.31, basic) and PA103 pilin (pH 4.53, acidic).  The DSL of PA683 pilin 
possesses an intermediate pH of 6.17(slightly acidic), which would suggest the 
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surrounding tertiary surface environment as the source of charge incompatibility or steric 
hindrance.   
 Western analysis of both pilin mutants also revealed what appeared to be 
significant degradation compared to expression of the unmutated pilin, which suggests 
these mutations target the pilin for destruction.  Future experiments, such as expressing 
PilO and the mutant pilins in strain 683 and engineering PA683 pilin with a longer C-
terminal peptide extension, would be performed in an attempt to optimize the 
glycosylation of mutant PA683 pilins.   
 
C.  Inability of the minimal –AAS peptide extension to permit glycosylation of a 
PA1244 PilA- E. coli alkaline phosphatase fusion protein.  Western blot analysis 
revealed that a PA1244 PilA- E. coli (EC) alkaline phosphatase (PhoA) fusion protein 
with a C-terminal –AAS peptide extension was unable to be glycosylated in P. 
aeruginosa.  These findings suggest that PilO is unable to access the C-terminal serine of 
the mutated fusion.  Recognition by PilO may be hindered by the bulky surface structure 
of EC PhoA, which may or may not be of compatible charge, and/or the lack of 
accessibility to pilin-specific structures.  Dimerization of PhoA monomers can be ruled 
out based on the established dimerization site demonstrated in Figure 13, which shows 
the C-termini of both monomers to be surface exposed.  With the possibility that the –
AAS peptide extesnion is unstable or is not accessible to PilO, Dr. Mohammed Qutyan 
engineered the fusion to present a longer peptide extension.  When the 15 amino acid 
peptide epitope of PA1244 used to engineer PA683 pilin was added to the C-terminus of 
the fusion (pPilApep), glycosylation was achieved.  This was accomplished by western 
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analysis using membrane fractions of broth grown PA103 wzyPaO11::aacC1 with anti-BAP 
and anti-O11 antibodies used as probes (personal communication, with M. Qutyan).  The 
longer peptide tail extension was able to extend the glycosylation site far enough away 
from the bulky surface of EC PhoA to permit interaction with PilO.  This finding, 
however, still does not rule out the necessity of pilin-specific structures or the necessity 
of membrane localization.   
 Additionally, western blot analysis revealed that both, original and mutated, 
fusion proteins were being targeted for degradation in all strains (E. coli, PA1244, and 
PA103 wzyPaO11::aacC1).  Degradation only showed up in immunoblots probed with anti-
BAP, while no pilin degradation was observed in blots probed with 5.44, which suggests 
that only the EC PhoA portion of the fusion was being targeted for cleavage.  The –AAS 
peptide extension may be getting targeted for cleavage, which could account for the lack 
of reaction with the primary antibody probes.  MALDI-TOF should be performed as a 
future experiment to confirm if both, original and mutated, fusions are being expressed as 
expected.    
 
D.  Inability of the minimal –AAS peptide extension to permit glycosylation of E. 
coli alkaline phosphatase.  Western blot analysis revealed that an E. coli alkaline 
phosphatase protein with a C-terminal –AAS peptide extension was unable to be 
glycosylated in P. aeruginosa.  The lack of PilO substrate recognition may have resulted 
from an inability to access the C-terminal serine residue of the mutated EC PhoA.  This 
may have been due to surface incompatibilities, such as steric hindrance or charge, the 
need for pilin-specific structures, or the necessity of a membrane anchor.  As with the 
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fusion protein, to circumvent the possibility that the –AAS peptide extension is unstable 
or is not accessible to PilO, Dr. Mohammed Qutyan engineered EC PhoA to present a 
longer peptide extension.  Periplasmic fractions of broth grown PA103 wzyPaO11::aacC1 
cells subjected to western analysis revealed that EC PhoA was able to be glycosylated 
when engineered with a 15 amino acid peptide tail extension (pECAPpep) (personal 
communication, with M. Qutyan).  These findings indicate that the lack of glycosylation 
of the EC PhoA-AAS construct resulted from surface environment incompatibilities and 
not on the necessity of pilin-specific structures or a membrane anchor.  However, these 
findings do not rule out the possibility that pilin-specific structures or membrane 
localization may enhance the glycosylation reaction.  In particular, membrane 
localization may make the substrate more readily accessible to PilO, since PilO is 
embedded in the same membrane.   
 As with the fusion constructs, the unmutated and mutated EC PhoA constructs 
should be subjected to MALDI-TOF analysis to determine whether or not these proteins 
are being expressed as expected.  If the –AAS tripeptide extension is being targeted for 
cleavage, these results may provide an additional explanation for the lack of reaction with 
primary antibody probes.   
 
E.  Significance to vaccine design.  Previous work from the Castric laboratory has 
demonstrated that PilO has low glycan substrate recognition (DiGiandomenico et al., 
2002; Horzempa et al., 2006b).  These findings suggest that a variety of O-antigens may 
be utilized to glycosylate pilin in P. aeruginosa.  The current findings provide further 
information on glycosylation substrate specificity, which has direct application to the 
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construction of vaccine components (Horzempa et al., 2006a; Horzempa et al., 2008).  
Specifically, other pilins may be used to produce a tripartite pilin vaccine composed of 
the pilin monomer, a glycosylation epitope, and an O-antigen subunit.  In the current 
case, PA683 pilin was engineered with a highly immunogenic PA1244 epitope tail 
(Castric & Deal, 1994), and covalently attached O11 O-antigen repeating unit.  A vaccine 
component of this nature has the potential to induce a protective immune response 
against PA683 pilin, PA1244 pilin, and the LPS surface layer of PA103.  This same 
manipulation may be applied to such pilins as that of N. gonorrhoeae, which has 
previously been shown to be expressed in P. aeruginosa (Hoyne et al., 1992).  The work 
done by Dr. Mohammed Qutyan, which demonstrated that EC PhoA could be 
glycosylated with the PA1244 peptide tail extension, further expands the potential for 
vaccine design.  These data suggest that non-pilin proteins, such as bacterial toxins, may 
be expressed in P. aeruginosa and glycosylated with O-antigen subunits.  Overall, the 
manipulation of the glycosylation machinery of P. aeruginosa portrays the potential to 
mix and match various antigens of bacterial pathogens, particularly gram-negatives, for 
the production of versatile vaccine components.   
 
F.  Were my thesis goals achieved?  Yes, my thesis goals were achieved.  The original 
study intended to assess the ability of a C-terminal –AAS peptide extension to 
glycosylate several normally, non-glycosylated proteins in P. aeruginosa.  After 
completing all –AAS constructs and observing glycosylation of only the PA683 pilin 
mutant, it was not in the best interest of time to apply the peptide tail extension (which 
also glycosylated PA683 pilin) to the fusion protein or EC PhoA.  Because of this high 
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risk endeavor, I focused on the TfpY study as my exit project, while Dr. Castric’s post-
doc, Dr. Mohammed Qutyan, in a collaborative publication attempt, constructed the last 
two peptide tail constructs, pPilAPpep and pECAPpep.     
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